WO2023201313A2 - Charged starch-based particles - Google Patents
Charged starch-based particles Download PDFInfo
- Publication number
- WO2023201313A2 WO2023201313A2 PCT/US2023/065747 US2023065747W WO2023201313A2 WO 2023201313 A2 WO2023201313 A2 WO 2023201313A2 US 2023065747 W US2023065747 W US 2023065747W WO 2023201313 A2 WO2023201313 A2 WO 2023201313A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- starch
- groups
- particles
- modified
- based particle
- Prior art date
Links
- 229920002472 Starch Polymers 0.000 title claims abstract description 459
- 235000019698 starch Nutrition 0.000 title claims abstract description 450
- 239000008107 starch Substances 0.000 title claims abstract description 440
- 239000002245 particle Substances 0.000 title claims abstract description 289
- 239000000203 mixture Substances 0.000 claims abstract description 119
- 238000000034 method Methods 0.000 claims abstract description 57
- 235000013305 food Nutrition 0.000 claims abstract description 31
- 239000002537 cosmetic Substances 0.000 claims abstract description 10
- 240000001592 Amaranthus caudatus Species 0.000 claims description 87
- 235000009328 Amaranthus caudatus Nutrition 0.000 claims description 87
- 239000004178 amaranth Substances 0.000 claims description 87
- 235000012735 amaranth Nutrition 0.000 claims description 87
- 229920000881 Modified starch Polymers 0.000 claims description 66
- 229920002261 Corn starch Polymers 0.000 claims description 51
- 239000004368 Modified starch Substances 0.000 claims description 51
- 239000008120 corn starch Substances 0.000 claims description 51
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 48
- -1 sulfonic groups Chemical group 0.000 claims description 39
- 239000002002 slurry Substances 0.000 claims description 27
- 150000007942 carboxylates Chemical group 0.000 claims description 22
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical group CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 claims description 22
- 125000002843 carboxylic acid group Chemical group 0.000 claims description 18
- 229920000856 Amylose Polymers 0.000 claims description 17
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical group CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 claims description 16
- 125000000129 anionic group Chemical group 0.000 claims description 15
- 125000002091 cationic group Chemical group 0.000 claims description 14
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium group Chemical group [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims description 11
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- 108090000623 proteins and genes Proteins 0.000 claims description 10
- 238000003860 storage Methods 0.000 claims description 10
- 230000004927 fusion Effects 0.000 claims description 9
- 229920001592 potato starch Polymers 0.000 claims description 9
- 239000000843 powder Substances 0.000 claims description 9
- 102000004169 proteins and genes Human genes 0.000 claims description 9
- 239000000725 suspension Substances 0.000 claims description 9
- 240000006162 Chenopodium quinoa Species 0.000 claims description 8
- 244000205754 Colocasia esculenta Species 0.000 claims description 8
- 235000006481 Colocasia esculenta Nutrition 0.000 claims description 8
- 240000005979 Hordeum vulgare Species 0.000 claims description 8
- 235000007340 Hordeum vulgare Nutrition 0.000 claims description 8
- 240000003183 Manihot esculenta Species 0.000 claims description 8
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 claims description 8
- 239000000499 gel Substances 0.000 claims description 8
- 239000004615 ingredient Substances 0.000 claims description 8
- 229940100445 wheat starch Drugs 0.000 claims description 8
- 235000013373 food additive Nutrition 0.000 claims description 7
- 239000002778 food additive Substances 0.000 claims description 7
- 229940100486 rice starch Drugs 0.000 claims description 7
- 150000003384 small molecules Chemical class 0.000 claims description 7
- 239000006228 supernatant Substances 0.000 claims description 7
- 239000002562 thickening agent Substances 0.000 claims description 7
- 150000001412 amines Chemical group 0.000 claims description 6
- 235000019426 modified starch Nutrition 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 5
- 239000006072 paste Substances 0.000 claims description 5
- 239000003826 tablet Substances 0.000 claims description 5
- 239000003242 anti bacterial agent Substances 0.000 claims description 4
- 229940088710 antibiotic agent Drugs 0.000 claims description 4
- 230000000887 hydrating effect Effects 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- 108020004459 Small interfering RNA Proteins 0.000 claims description 3
- 229940035676 analgesics Drugs 0.000 claims description 3
- 229940035674 anesthetics Drugs 0.000 claims description 3
- 239000000730 antalgic agent Substances 0.000 claims description 3
- 229940121375 antifungal agent Drugs 0.000 claims description 3
- 239000003443 antiviral agent Substances 0.000 claims description 3
- 229940121357 antivirals Drugs 0.000 claims description 3
- 239000012829 chemotherapy agent Substances 0.000 claims description 3
- 239000002299 complementary DNA Substances 0.000 claims description 3
- 235000011950 custard Nutrition 0.000 claims description 3
- 239000003193 general anesthetic agent Substances 0.000 claims description 3
- 239000000314 lubricant Substances 0.000 claims description 3
- 108020004999 messenger RNA Proteins 0.000 claims description 3
- 235000011962 puddings Nutrition 0.000 claims description 3
- 235000015067 sauces Nutrition 0.000 claims description 3
- 235000014347 soups Nutrition 0.000 claims description 3
- 208000035484 Cellulite Diseases 0.000 claims description 2
- 206010049752 Peau d'orange Diseases 0.000 claims description 2
- 230000002141 anti-parasite Effects 0.000 claims description 2
- 239000003096 antiparasitic agent Substances 0.000 claims description 2
- 229940125687 antiparasitic agent Drugs 0.000 claims description 2
- 235000021185 dessert Nutrition 0.000 claims description 2
- 238000011049 filling Methods 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 3
- 229940099112 cornstarch Drugs 0.000 description 42
- 239000008187 granular material Substances 0.000 description 30
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 28
- 239000003112 inhibitor Substances 0.000 description 27
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- 235000019441 ethanol Nutrition 0.000 description 15
- 238000012545 processing Methods 0.000 description 12
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 10
- 238000013459 approach Methods 0.000 description 10
- 238000005119 centrifugation Methods 0.000 description 10
- 238000011534 incubation Methods 0.000 description 10
- 229920000642 polymer Polymers 0.000 description 10
- 230000004048 modification Effects 0.000 description 9
- 238000012986 modification Methods 0.000 description 9
- 239000000463 material Substances 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- 125000000217 alkyl group Chemical group 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 238000001338 self-assembly Methods 0.000 description 7
- 239000001257 hydrogen Substances 0.000 description 6
- 229910052739 hydrogen Inorganic materials 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 239000013049 sediment Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000001157 Fourier transform infrared spectrum Methods 0.000 description 5
- 238000002441 X-ray diffraction Methods 0.000 description 5
- 230000018044 dehydration Effects 0.000 description 5
- 238000006297 dehydration reaction Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000009881 electrostatic interaction Effects 0.000 description 5
- PUVAFTRIIUSGLK-UHFFFAOYSA-M trimethyl(oxiran-2-ylmethyl)azanium;chloride Chemical compound [Cl-].C[N+](C)(C)CC1CO1 PUVAFTRIIUSGLK-UHFFFAOYSA-M 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 229940124647 MEK inhibitor Drugs 0.000 description 4
- 241001467552 Mycobacterium bovis BCG Species 0.000 description 4
- 239000004793 Polystyrene Substances 0.000 description 4
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 4
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 229960004679 doxorubicin Drugs 0.000 description 4
- 238000005189 flocculation Methods 0.000 description 4
- 230000016615 flocculation Effects 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 230000036961 partial effect Effects 0.000 description 4
- 239000008177 pharmaceutical agent Substances 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 229920002223 polystyrene Polymers 0.000 description 4
- 229940116317 potato starch Drugs 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 4
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 4
- 229960004528 vincristine Drugs 0.000 description 4
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical group OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 102000001301 EGF receptor Human genes 0.000 description 3
- 108060006698 EGF receptor Proteins 0.000 description 3
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 3
- 108010000817 Leuprolide Proteins 0.000 description 3
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 230000002280 anti-androgenic effect Effects 0.000 description 3
- 239000000051 antiandrogen Substances 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 229960004630 chlorambucil Drugs 0.000 description 3
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 3
- FOCAUTSVDIKZOP-UHFFFAOYSA-N chloroacetic acid Chemical compound OC(=O)CCl FOCAUTSVDIKZOP-UHFFFAOYSA-N 0.000 description 3
- 229940106681 chloroacetic acid Drugs 0.000 description 3
- 238000010494 dissociation reaction Methods 0.000 description 3
- 230000005593 dissociations Effects 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 229940011871 estrogen Drugs 0.000 description 3
- 239000000262 estrogen Substances 0.000 description 3
- 239000000328 estrogen antagonist Substances 0.000 description 3
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 3
- 235000013312 flour Nutrition 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 3
- 229960005277 gemcitabine Drugs 0.000 description 3
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 3
- 229960004768 irinotecan Drugs 0.000 description 3
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 3
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 3
- 229960004338 leuprorelin Drugs 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000002715 modification method Methods 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 238000001878 scanning electron micrograph Methods 0.000 description 3
- CYOHGALHFOKKQC-UHFFFAOYSA-N selumetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1Cl CYOHGALHFOKKQC-UHFFFAOYSA-N 0.000 description 3
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 3
- 229960000303 topotecan Drugs 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- KOQIAZNBAWFSQM-UHFFFAOYSA-N 2-[4-(3-ethynylanilino)-7-(2-methoxyethoxy)quinazolin-6-yl]oxyethanol Chemical compound C=12C=C(OCCO)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 KOQIAZNBAWFSQM-UHFFFAOYSA-N 0.000 description 2
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 2
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 2
- 238000004483 ATR-FTIR spectroscopy Methods 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 2
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 2
- 229940124297 CDK 4/6 inhibitor Drugs 0.000 description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 2
- 108010092160 Dactinomycin Proteins 0.000 description 2
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 2
- 102100031480 Dual specificity mitogen-activated protein kinase kinase 1 Human genes 0.000 description 2
- 101710146526 Dual specificity mitogen-activated protein kinase kinase 1 Proteins 0.000 description 2
- 102100023266 Dual specificity mitogen-activated protein kinase kinase 2 Human genes 0.000 description 2
- 101710146529 Dual specificity mitogen-activated protein kinase kinase 2 Proteins 0.000 description 2
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 2
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 2
- 102000006992 Interferon-alpha Human genes 0.000 description 2
- 108010047761 Interferon-alpha Proteins 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 2
- 239000013283 Janus particle Substances 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 2
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 2
- 239000002067 L01XE06 - Dasatinib Substances 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 2
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 229960001686 afatinib Drugs 0.000 description 2
- ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 229940046836 anti-estrogen Drugs 0.000 description 2
- 230000001833 anti-estrogenic effect Effects 0.000 description 2
- 229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 description 2
- HJBWBFZLDZWPHF-UHFFFAOYSA-N apalutamide Chemical compound C1=C(F)C(C(=O)NC)=CC=C1N1C2(CCC2)C(=O)N(C=2C=C(C(C#N)=NC=2)C(F)(F)F)C1=S HJBWBFZLDZWPHF-UHFFFAOYSA-N 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 229960002092 busulfan Drugs 0.000 description 2
- 229960001948 caffeine Drugs 0.000 description 2
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 2
- 229930195731 calicheamicin Natural products 0.000 description 2
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical class C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 2
- 229950002826 canertinib Drugs 0.000 description 2
- OMZCMEYTWSXEPZ-UHFFFAOYSA-N canertinib Chemical compound C1=C(Cl)C(F)=CC=C1NC1=NC=NC2=CC(OCCCN3CCOCC3)=C(NC(=O)C=C)C=C12 OMZCMEYTWSXEPZ-UHFFFAOYSA-N 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 229960004562 carboplatin Drugs 0.000 description 2
- 239000013626 chemical specie Substances 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 229960002271 cobimetinib Drugs 0.000 description 2
- BSMCAPRUBJMWDF-KRWDZBQOSA-N cobimetinib Chemical compound C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F BSMCAPRUBJMWDF-KRWDZBQOSA-N 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 229960004397 cyclophosphamide Drugs 0.000 description 2
- 229960000684 cytarabine Drugs 0.000 description 2
- LVXJQMNHJWSHET-AATRIKPKSA-N dacomitinib Chemical compound C=12C=C(NC(=O)\C=C\CN3CCCCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 LVXJQMNHJWSHET-AATRIKPKSA-N 0.000 description 2
- 229960002448 dasatinib Drugs 0.000 description 2
- 229960000975 daunorubicin Drugs 0.000 description 2
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- 230000003292 diminished effect Effects 0.000 description 2
- AMRJKAQTDDKMCE-UHFFFAOYSA-N dolastatin Chemical compound CC(C)C(N(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(C(C)C)C(OC)CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(C=1SC=CN=1)CC1=CC=CC=C1 AMRJKAQTDDKMCE-UHFFFAOYSA-N 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 229960001904 epirubicin Drugs 0.000 description 2
- 229960001433 erlotinib Drugs 0.000 description 2
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 2
- 229960005420 etoposide Drugs 0.000 description 2
- LIQODXNTTZAGID-OCBXBXKTSA-N etoposide phosphate Chemical compound COC1=C(OP(O)(O)=O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 LIQODXNTTZAGID-OCBXBXKTSA-N 0.000 description 2
- 229960000752 etoposide phosphate Drugs 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 229960004039 finasteride Drugs 0.000 description 2
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 2
- 229960000390 fludarabine Drugs 0.000 description 2
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 2
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 2
- 229960002074 flutamide Drugs 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- CHPZKNULDCNCBW-UHFFFAOYSA-N gallium nitrate Chemical compound [Ga+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O CHPZKNULDCNCBW-UHFFFAOYSA-N 0.000 description 2
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 2
- 229960002584 gefitinib Drugs 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 238000010335 hydrothermal treatment Methods 0.000 description 2
- 229960002411 imatinib Drugs 0.000 description 2
- 229960001438 immunostimulant agent Drugs 0.000 description 2
- 239000003022 immunostimulating agent Substances 0.000 description 2
- 230000003308 immunostimulating effect Effects 0.000 description 2
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 2
- 229960001924 melphalan Drugs 0.000 description 2
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 229960004857 mitomycin Drugs 0.000 description 2
- 229960001156 mitoxantrone Drugs 0.000 description 2
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 2
- 229950008835 neratinib Drugs 0.000 description 2
- ZNHPZUKZSNBOSQ-BQYQJAHWSA-N neratinib Chemical compound C=12C=C(NC\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 ZNHPZUKZSNBOSQ-BQYQJAHWSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- WVUNYSQLFKLYNI-AATRIKPKSA-N pelitinib Chemical compound C=12C=C(NC(=O)\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC1=CC=C(F)C(Cl)=C1 WVUNYSQLFKLYNI-AATRIKPKSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 2
- 229960004618 prednisone Drugs 0.000 description 2
- UOWVMDUEMSNCAV-WYENRQIDSA-N rachelmycin Chemical compound C1([C@]23C[C@@H]2CN1C(=O)C=1NC=2C(OC)=C(O)C4=C(C=2C=1)CCN4C(=O)C1=CC=2C=4CCN(C=4C(O)=C(C=2N1)OC)C(N)=O)=CC(=O)C1=C3C(C)=CN1 UOWVMDUEMSNCAV-WYENRQIDSA-N 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000004626 scanning electron microscopy Methods 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 229960003787 sorafenib Drugs 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 229950007866 tanespimycin Drugs 0.000 description 2
- AYUNIORJHRXIBJ-TXHRRWQRSA-N tanespimycin Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](O)[C@@H](OC)C[C@H](C)CC2=C(NCC=C)C(=O)C=C1C2=O AYUNIORJHRXIBJ-TXHRRWQRSA-N 0.000 description 2
- 229960001196 thiotepa Drugs 0.000 description 2
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
- 229960004066 trametinib Drugs 0.000 description 2
- LIRYPHYGHXZJBZ-UHFFFAOYSA-N trametinib Chemical compound CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 description 2
- 229960003862 vemurafenib Drugs 0.000 description 2
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 description 2
- 229960003048 vinblastine Drugs 0.000 description 2
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 2
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 2
- 229960004355 vindesine Drugs 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- UCJZOKGUEJUNIO-IINYFYTJSA-N (3S,4S)-8-[6-amino-5-(2-amino-3-chloropyridin-4-yl)sulfanylpyrazin-2-yl]-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine Chemical compound C[C@@H]1OCC2(CCN(CC2)C2=CN=C(SC3=C(Cl)C(N)=NC=C3)C(N)=N2)[C@@H]1N UCJZOKGUEJUNIO-IINYFYTJSA-N 0.000 description 1
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- UQVNRKBFAXNOGA-LWTNMJDUSA-N (E)-tomaymycin Chemical compound CO[C@H]1NC2=CC(O)=C(OC)C=C2C(=O)N2C\C(=C\C)C[C@@H]12 UQVNRKBFAXNOGA-LWTNMJDUSA-N 0.000 description 1
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- JCIIKRHCWVHVFF-UHFFFAOYSA-N 1,2,4-thiadiazol-5-amine;hydrochloride Chemical compound Cl.NC1=NC=NS1 JCIIKRHCWVHVFF-UHFFFAOYSA-N 0.000 description 1
- 102100025573 1-alkyl-2-acetylglycerophosphocholine esterase Human genes 0.000 description 1
- 101710175516 14 kDa zinc-binding protein Proteins 0.000 description 1
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 1
- RWEVIPRMPFNTLO-UHFFFAOYSA-N 2-(2-fluoro-4-iodoanilino)-N-(2-hydroxyethoxy)-1,5-dimethyl-6-oxo-3-pyridinecarboxamide Chemical compound CN1C(=O)C(C)=CC(C(=O)NOCCO)=C1NC1=CC=C(I)C=C1F RWEVIPRMPFNTLO-UHFFFAOYSA-N 0.000 description 1
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 1
- MHXVDXXARZCVRK-WCWDXBQESA-N 2-[2-[4-[(e)-3,3,3-trifluoro-1,2-diphenylprop-1-enyl]phenoxy]ethylamino]ethanol Chemical compound C1=CC(OCCNCCO)=CC=C1C(\C=1C=CC=CC=1)=C(C(F)(F)F)/C1=CC=CC=C1 MHXVDXXARZCVRK-WCWDXBQESA-N 0.000 description 1
- PXJJOGITBQXZEQ-JTHROIFXSA-M 2-[4-[(z)-1,2-diphenylbut-1-enyl]phenoxy]ethyl-trimethylazanium;iodide Chemical compound [I-].C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCC[N+](C)(C)C)=CC=1)/C1=CC=CC=C1 PXJJOGITBQXZEQ-JTHROIFXSA-M 0.000 description 1
- OTLLEIBWKHEHGU-UHFFFAOYSA-N 2-[5-[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy]-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-4-phosphonooxyhexanedioic acid Chemical compound C1=NC=2C(N)=NC=NC=2N1C(C(C1O)O)OC1COC1C(CO)OC(OC(C(O)C(OP(O)(O)=O)C(O)C(O)=O)C(O)=O)C(O)C1O OTLLEIBWKHEHGU-UHFFFAOYSA-N 0.000 description 1
- CTRPRMNBTVRDFH-UHFFFAOYSA-N 2-n-methyl-1,3,5-triazine-2,4,6-triamine Chemical class CNC1=NC(N)=NC(N)=N1 CTRPRMNBTVRDFH-UHFFFAOYSA-N 0.000 description 1
- RCLQNICOARASSR-SECBINFHSA-N 3-[(2r)-2,3-dihydroxypropyl]-6-fluoro-5-(2-fluoro-4-iodoanilino)-8-methylpyrido[2,3-d]pyrimidine-4,7-dione Chemical compound FC=1C(=O)N(C)C=2N=CN(C[C@@H](O)CO)C(=O)C=2C=1NC1=CC=C(I)C=C1F RCLQNICOARASSR-SECBINFHSA-N 0.000 description 1
- CLPFFLWZZBQMAO-UHFFFAOYSA-N 4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)benzonitrile Chemical compound C1=CC(C#N)=CC=C1C1N2C=NC=C2CCC1 CLPFFLWZZBQMAO-UHFFFAOYSA-N 0.000 description 1
- BJNWUKRWOQERPQ-UHFFFAOYSA-N 4-[3-[[2-amino-5-[2-(1-methylpiperidin-4-yl)-1,3-thiazol-5-yl]pyridin-3-yl]oxymethyl]phenyl]-2-methylbut-3-yn-2-ol Chemical compound C(C1=CC(C#CC(C)(O)C)=CC=C1)OC1=C(N=CC(C=2SC(C3CCN(CC3)C)=NC=2)=C1)N BJNWUKRWOQERPQ-UHFFFAOYSA-N 0.000 description 1
- UWXSAYUXVSFDBQ-CYBMUJFWSA-N 4-n-[3-chloro-4-(1,3-thiazol-2-ylmethoxy)phenyl]-6-n-[(4r)-4-methyl-4,5-dihydro-1,3-oxazol-2-yl]quinazoline-4,6-diamine Chemical compound C[C@@H]1COC(NC=2C=C3C(NC=4C=C(Cl)C(OCC=5SC=CN=5)=CC=4)=NC=NC3=CC=2)=N1 UWXSAYUXVSFDBQ-CYBMUJFWSA-N 0.000 description 1
- MUOKSQABCJCOPU-UHFFFAOYSA-N 5-(3-chloroanilino)benzo[c][2,6]naphthyridine-8-carboxylic acid Chemical compound C=1C(C(=O)O)=CC=C(C2=CN=CC=C22)C=1N=C2NC1=CC=CC(Cl)=C1 MUOKSQABCJCOPU-UHFFFAOYSA-N 0.000 description 1
- IDPUKCWIGUEADI-UHFFFAOYSA-N 5-[bis(2-chloroethyl)amino]uracil Chemical compound ClCCN(CCCl)C1=CNC(=O)NC1=O IDPUKCWIGUEADI-UHFFFAOYSA-N 0.000 description 1
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 description 1
- YHSMSRREJYOGQJ-UHFFFAOYSA-N 5-nonyloxytryptamine Chemical compound CCCCCCCCCOC1=CC=C2NC=C(CCN)C2=C1 YHSMSRREJYOGQJ-UHFFFAOYSA-N 0.000 description 1
- SDEAXTCZPQIFQM-UHFFFAOYSA-N 6-n-(4,4-dimethyl-5h-1,3-oxazol-2-yl)-4-n-[3-methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]quinazoline-4,6-diamine Chemical compound C=1C=C(OC2=CC3=NC=NN3C=C2)C(C)=CC=1NC(C1=C2)=NC=NC1=CC=C2NC1=NC(C)(C)CO1 SDEAXTCZPQIFQM-UHFFFAOYSA-N 0.000 description 1
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 1
- PLIVFNIUGLLCEK-UHFFFAOYSA-N 7-[4-(3-ethynylanilino)-7-methoxyquinazolin-6-yl]oxy-n-hydroxyheptanamide Chemical compound C=12C=C(OCCCCCCC(=O)NO)C(OC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 PLIVFNIUGLLCEK-UHFFFAOYSA-N 0.000 description 1
- GOJJWDOZNKBUSR-UHFFFAOYSA-N 7-sulfamoyloxyheptyl sulfamate Chemical compound NS(=O)(=O)OCCCCCCCOS(N)(=O)=O GOJJWDOZNKBUSR-UHFFFAOYSA-N 0.000 description 1
- OONFNUWBHFSNBT-HXUWFJFHSA-N AEE788 Chemical compound C1CN(CC)CCN1CC1=CC=C(C=2NC3=NC=NC(N[C@H](C)C=4C=CC=CC=4)=C3C=2)C=C1 OONFNUWBHFSNBT-HXUWFJFHSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- 229910002710 Au-Pd Inorganic materials 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 229940125431 BRAF inhibitor Drugs 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 description 1
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 description 1
- 102100028989 C-X-C chemokine receptor type 2 Human genes 0.000 description 1
- 229940124292 CD20 monoclonal antibody Drugs 0.000 description 1
- LLVZBTWPGQVVLW-SNAWJCMRSA-N CP-724714 Chemical compound C12=CC(/C=C/CNC(=O)COC)=CC=C2N=CN=C1NC(C=C1C)=CC=C1OC1=CC=C(C)N=C1 LLVZBTWPGQVVLW-SNAWJCMRSA-N 0.000 description 1
- FVLVBPDQNARYJU-XAHDHGMMSA-N C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O Chemical compound C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O FVLVBPDQNARYJU-XAHDHGMMSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
- 239000005461 Canertinib Substances 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- 102000005403 Casein Kinases Human genes 0.000 description 1
- 108010031425 Casein Kinases Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 229910002483 Cu Ka Inorganic materials 0.000 description 1
- 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 description 1
- 102100036239 Cyclin-dependent kinase 2 Human genes 0.000 description 1
- 102100026810 Cyclin-dependent kinase 7 Human genes 0.000 description 1
- 102100036466 Delta-like protein 3 Human genes 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- QXRSDHAAWVKZLJ-OXZHEXMSSA-N Epothilone B Natural products O=C1[C@H](C)[C@H](O)[C@@H](C)CCC[C@@]2(C)O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C QXRSDHAAWVKZLJ-OXZHEXMSSA-N 0.000 description 1
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- JRZJKWGQFNTSRN-UHFFFAOYSA-N Geldanamycin Natural products C1C(C)CC(OC)C(O)C(C)C=C(C)C(OC(N)=O)C(OC)CCC=C(C)C(=O)NC2=CC(=O)C(OC)=C1C2=O JRZJKWGQFNTSRN-UHFFFAOYSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 1
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
- 108010069236 Goserelin Proteins 0.000 description 1
- 101000911952 Homo sapiens Cyclin-dependent kinase 7 Proteins 0.000 description 1
- 101000928513 Homo sapiens Delta-like protein 3 Proteins 0.000 description 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
- 101000916644 Homo sapiens Macrophage colony-stimulating factor 1 receptor Proteins 0.000 description 1
- 101001059991 Homo sapiens Mitogen-activated protein kinase kinase kinase kinase 1 Proteins 0.000 description 1
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 description 1
- 101001087394 Homo sapiens Tyrosine-protein phosphatase non-receptor type 1 Proteins 0.000 description 1
- 101001135572 Homo sapiens Tyrosine-protein phosphatase non-receptor type 2 Proteins 0.000 description 1
- 101001135589 Homo sapiens Tyrosine-protein phosphatase non-receptor type 22 Proteins 0.000 description 1
- 101000617285 Homo sapiens Tyrosine-protein phosphatase non-receptor type 6 Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- DOMWKUIIPQCAJU-LJHIYBGHSA-N Hydroxyprogesterone caproate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)CCCCC)[C@@]1(C)CC2 DOMWKUIIPQCAJU-LJHIYBGHSA-N 0.000 description 1
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 1
- 108010018951 Interleukin-8B Receptors Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 1
- 239000002136 L01XE07 - Lapatinib Substances 0.000 description 1
- 239000002118 L01XE12 - Vandetanib Substances 0.000 description 1
- 229930190887 Leptomycin Natural products 0.000 description 1
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 description 1
- 102000004318 Matrilysin Human genes 0.000 description 1
- 108090000855 Matrilysin Proteins 0.000 description 1
- 102000000422 Matrix Metalloproteinase 3 Human genes 0.000 description 1
- 102000008135 Mechanistic Target of Rapamycin Complex 1 Human genes 0.000 description 1
- 108010035196 Mechanistic Target of Rapamycin Complex 1 Proteins 0.000 description 1
- 102000003735 Mesothelin Human genes 0.000 description 1
- 108090000015 Mesothelin Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102100028199 Mitogen-activated protein kinase kinase kinase kinase 1 Human genes 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 102100030173 Muellerian-inhibiting factor Human genes 0.000 description 1
- MVZGYPSXNDCANY-UHFFFAOYSA-N N-[4-[3-chloro-4-[(3-fluorophenyl)methoxy]anilino]-6-quinazolinyl]-2-propenamide Chemical compound FC1=CC=CC(COC=2C(=CC(NC=3C4=CC(NC(=O)C=C)=CC=C4N=CN=3)=CC=2)Cl)=C1 MVZGYPSXNDCANY-UHFFFAOYSA-N 0.000 description 1
- LKJPYSCBVHEWIU-UHFFFAOYSA-N N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide Chemical compound C=1C=C(C#N)C(C(F)(F)F)=CC=1NC(=O)C(O)(C)CS(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-UHFFFAOYSA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 102100035486 Nectin-4 Human genes 0.000 description 1
- 101710043865 Nectin-4 Proteins 0.000 description 1
- 101710204212 Neocarzinostatin Proteins 0.000 description 1
- HBPQPBSTHOHSFP-UHFFFAOYSA-N OC(=O)C([Pt])=O Chemical compound OC(=O)C([Pt])=O HBPQPBSTHOHSFP-UHFFFAOYSA-N 0.000 description 1
- 239000012661 PARP inhibitor Substances 0.000 description 1
- 101150038994 PDGFRA gene Proteins 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 1
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 102000010752 Plasminogen Inactivators Human genes 0.000 description 1
- 108010077971 Plasminogen Inactivators Proteins 0.000 description 1
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 229940079156 Proteasome inhibitor Drugs 0.000 description 1
- 229940123924 Protein kinase C inhibitor Drugs 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 229940126002 RMC-4630 Drugs 0.000 description 1
- 229940078123 Ras inhibitor Drugs 0.000 description 1
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 description 1
- ZQUSFAUAYSEREK-WKILWMFISA-N SB-239063 Chemical compound COC1=NC=CC(C=2N(C=NC=2C=2C=CC(F)=CC=2)[C@@H]2CC[C@@H](O)CC2)=N1 ZQUSFAUAYSEREK-WKILWMFISA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 229940125811 TNO155 Drugs 0.000 description 1
- PDMMFKSKQVNJMI-BLQWBTBKSA-N Testosterone propionate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CC)[C@@]1(C)CC2 PDMMFKSKQVNJMI-BLQWBTBKSA-N 0.000 description 1
- 102000011923 Thyrotropin Human genes 0.000 description 1
- 108010061174 Thyrotropin Proteins 0.000 description 1
- UQVNRKBFAXNOGA-IUODEOHRSA-N Tomaymycin Natural products CO[C@H]1Nc2cc(O)c(OC)cc2C(=O)N3CC(=CC)C[C@H]13 UQVNRKBFAXNOGA-IUODEOHRSA-N 0.000 description 1
- IVTVGDXNLFLDRM-HNNXBMFYSA-N Tomudex Chemical compound C=1C=C2NC(C)=NC(=O)C2=CC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)S1 IVTVGDXNLFLDRM-HNNXBMFYSA-N 0.000 description 1
- DFBIRQPKNDILPW-CIVMWXNOSA-N Triptolide Chemical compound O=C1OCC([C@@H]2C3)=C1CC[C@]2(C)[C@]12O[C@H]1[C@@H]1O[C@]1(C(C)C)[C@@H](O)[C@]21[C@H]3O1 DFBIRQPKNDILPW-CIVMWXNOSA-N 0.000 description 1
- 102100033001 Tyrosine-protein phosphatase non-receptor type 1 Human genes 0.000 description 1
- 102100033019 Tyrosine-protein phosphatase non-receptor type 11 Human genes 0.000 description 1
- 101710116241 Tyrosine-protein phosphatase non-receptor type 11 Proteins 0.000 description 1
- 102100033141 Tyrosine-protein phosphatase non-receptor type 2 Human genes 0.000 description 1
- 102100033138 Tyrosine-protein phosphatase non-receptor type 22 Human genes 0.000 description 1
- 102100021657 Tyrosine-protein phosphatase non-receptor type 6 Human genes 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- LUJZZYWHBDHDQX-QFIPXVFZSA-N [(3s)-morpholin-3-yl]methyl n-[4-[[1-[(3-fluorophenyl)methyl]indazol-5-yl]amino]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamate Chemical compound C=1N2N=CN=C(NC=3C=C4C=NN(CC=5C=C(F)C=CC=5)C4=CC=3)C2=C(C)C=1NC(=O)OC[C@@H]1COCCN1 LUJZZYWHBDHDQX-QFIPXVFZSA-N 0.000 description 1
- IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 description 1
- HISJAYUQVHMWTA-BLLLJJGKSA-N [6-(2-amino-3-chloropyridin-4-yl)sulfanyl-3-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-5-methylpyrazin-2-yl]methanol Chemical compound NC1=NC=CC(=C1Cl)SC1=C(N=C(C(=N1)CO)N1CCC2([C@@H]([C@@H](OC2)C)N)CC1)C HISJAYUQVHMWTA-BLLLJJGKSA-N 0.000 description 1
- GZOSMCIZMLWJML-VJLLXTKPSA-N abiraterone Chemical compound C([C@H]1[C@H]2[C@@H]([C@]3(CC[C@H](O)CC3=CC2)C)CC[C@@]11C)C=C1C1=CC=CN=C1 GZOSMCIZMLWJML-VJLLXTKPSA-N 0.000 description 1
- 229960000853 abiraterone Drugs 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 229930183665 actinomycin Natural products 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000001780 adrenocortical effect Effects 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000002355 alkine group Chemical group 0.000 description 1
- 150000004703 alkoxides Chemical group 0.000 description 1
- 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 229960003437 aminoglutethimide Drugs 0.000 description 1
- ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 1
- 229960001220 amsacrine Drugs 0.000 description 1
- XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229960002932 anastrozole Drugs 0.000 description 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- ACPOUJIDANTYHO-UHFFFAOYSA-N anthra[1,9-cd]pyrazol-6(2H)-one Chemical compound C1=CC(C(=O)C=2C3=CC=CC=2)=C2C3=NNC2=C1 ACPOUJIDANTYHO-UHFFFAOYSA-N 0.000 description 1
- RGHILYZRVFRRNK-UHFFFAOYSA-N anthracene-1,2-dione Chemical compound C1=CC=C2C=C(C(C(=O)C=C3)=O)C3=CC2=C1 RGHILYZRVFRRNK-UHFFFAOYSA-N 0.000 description 1
- 239000003817 anthracycline antibiotic agent Substances 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 1
- 102000025171 antigen binding proteins Human genes 0.000 description 1
- 108091000831 antigen binding proteins Proteins 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 229940045985 antineoplastic platinum compound Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 229950007511 apalutamide Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 239000003886 aromatase inhibitor Substances 0.000 description 1
- 229940046844 aromatase inhibitors Drugs 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 229960000997 bicalutamide Drugs 0.000 description 1
- ACWZRVQXLIRSDF-UHFFFAOYSA-N binimetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1F ACWZRVQXLIRSDF-UHFFFAOYSA-N 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 150000001642 boronic acid derivatives Chemical class 0.000 description 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 1
- 229960001467 bortezomib Drugs 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 229940127093 camptothecin Drugs 0.000 description 1
- 229960004117 capecitabine Drugs 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 230000021523 carboxylation Effects 0.000 description 1
- 238000006473 carboxylation reaction Methods 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229940097647 casodex Drugs 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 description 1
- 229960005110 cerivastatin Drugs 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- ZWVZORIKUNOTCS-OAQYLSRUSA-N chembl401930 Chemical compound C1([C@H](O)CNC2=C(C(NC=C2)=O)C=2NC=3C=C(C=C(C=3N=2)C)N2CCOCC2)=CC=CC(Cl)=C1 ZWVZORIKUNOTCS-OAQYLSRUSA-N 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- WDQPAMHFFCXSNU-BGABXYSRSA-N clofazimine Chemical compound C12=CC=CC=C2N=C2C=C(NC=3C=CC(Cl)=CC=3)C(=N/C(C)C)/C=C2N1C1=CC=C(Cl)C=C1 WDQPAMHFFCXSNU-BGABXYSRSA-N 0.000 description 1
- 229960004287 clofazimine Drugs 0.000 description 1
- GKIRPKYJQBWNGO-OCEACIFDSA-N clomifene Chemical class C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(\Cl)C1=CC=CC=C1 GKIRPKYJQBWNGO-OCEACIFDSA-N 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- BFSMGDJOXZAERB-UHFFFAOYSA-N dabrafenib Chemical compound S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 BFSMGDJOXZAERB-UHFFFAOYSA-N 0.000 description 1
- 229960002465 dabrafenib Drugs 0.000 description 1
- 229950002205 dacomitinib Drugs 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 229940127276 delta-like ligand 3 Drugs 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 235000011850 desserts Nutrition 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- FLISWPFVWWWNNP-BQYQJAHWSA-N dihydro-3-(1-octenyl)-2,5-furandione Chemical compound CCCCCC\C=C\C1CC(=O)OC1=O FLISWPFVWWWNNP-BQYQJAHWSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 229930188854 dolastatin Natural products 0.000 description 1
- 235000015071 dressings Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229960005501 duocarmycin Drugs 0.000 description 1
- VQNATVDKACXKTF-XELLLNAOSA-N duocarmycin Chemical class COC1=C(OC)C(OC)=C2NC(C(=O)N3C4=CC(=O)C5=C([C@@]64C[C@@H]6C3)C=C(N5)C(=O)OC)=CC2=C1 VQNATVDKACXKTF-XELLLNAOSA-N 0.000 description 1
- 229930184221 duocarmycin Natural products 0.000 description 1
- 229940121647 egfr inhibitor Drugs 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229960004671 enzalutamide Drugs 0.000 description 1
- WXCXUHSOUPDCQV-UHFFFAOYSA-N enzalutamide Chemical compound C1=C(F)C(C(=O)NC)=CC=C1N1C(C)(C)C(=O)N(C=2C=C(C(C#N)=CC=2)C(F)(F)F)C1=S WXCXUHSOUPDCQV-UHFFFAOYSA-N 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- YJGVMLPVUAXIQN-UHFFFAOYSA-N epipodophyllotoxin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YJGVMLPVUAXIQN-UHFFFAOYSA-N 0.000 description 1
- 229930013356 epothilone Natural products 0.000 description 1
- HESCAJZNRMSMJG-HGYUPSKWSA-N epothilone A Natural products O=C1[C@H](C)[C@H](O)[C@H](C)CCC[C@H]2O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C HESCAJZNRMSMJG-HGYUPSKWSA-N 0.000 description 1
- HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical class C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 description 1
- QXRSDHAAWVKZLJ-PVYNADRNSA-N epothilone B Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 QXRSDHAAWVKZLJ-PVYNADRNSA-N 0.000 description 1
- WCDWBPCFGJXFJZ-UHFFFAOYSA-N etanidazole Chemical compound OCCNC(=O)CN1C=CN=C1[N+]([O-])=O WCDWBPCFGJXFJZ-UHFFFAOYSA-N 0.000 description 1
- 229950006566 etanidazole Drugs 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- 229960002568 ethinylestradiol Drugs 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 229960000255 exemestane Drugs 0.000 description 1
- 239000002095 exotoxin Substances 0.000 description 1
- 231100000776 exotoxin Toxicity 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229950011548 fadrozole Drugs 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 229960001751 fluoxymesterone Drugs 0.000 description 1
- YLRFCQOZQXIBAB-RBZZARIASA-N fluoxymesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)C[C@@H]2O YLRFCQOZQXIBAB-RBZZARIASA-N 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 229940014144 folate Drugs 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 150000002224 folic acids Chemical class 0.000 description 1
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 1
- 235000008191 folinic acid Nutrition 0.000 description 1
- 239000011672 folinic acid Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 229940044658 gallium nitrate Drugs 0.000 description 1
- 239000002406 gelatinase inhibitor Substances 0.000 description 1
- QTQAWLPCGQOSGP-GBTDJJJQSA-N geldanamycin Chemical compound N1C(=O)\C(C)=C/C=C\[C@@H](OC)[C@H](OC(N)=O)\C(C)=C/[C@@H](C)[C@@H](O)[C@H](OC)C[C@@H](C)CC2=C(OC)C(=O)C=C1C2=O QTQAWLPCGQOSGP-GBTDJJJQSA-N 0.000 description 1
- 229940080856 gleevec Drugs 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
- 229940035638 gonadotropin-releasing hormone Drugs 0.000 description 1
- 229960002913 goserelin Drugs 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 231100001261 hazardous Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000000703 high-speed centrifugation Methods 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- HYFHYPWGAURHIV-UHFFFAOYSA-N homoharringtonine Natural products C1=C2CCN3CCCC43C=C(OC)C(OC(=O)C(O)(CCCC(C)(C)O)CC(=O)OC)C4C2=CC2=C1OCO2 HYFHYPWGAURHIV-UHFFFAOYSA-N 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 229960001330 hydroxycarbamide Drugs 0.000 description 1
- 229950000801 hydroxyprogesterone caproate Drugs 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 229940051026 immunotoxin Drugs 0.000 description 1
- 230000002637 immunotoxin Effects 0.000 description 1
- 239000002596 immunotoxin Substances 0.000 description 1
- 231100000608 immunotoxin Toxicity 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000001023 inorganic pigment Substances 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229960004130 itraconazole Drugs 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 229960004891 lapatinib Drugs 0.000 description 1
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- YACHGFWEQXFSBS-RJXCBBHPSA-N leptomycin Chemical compound OC(=O)/C=C(C)/C[C@H](C)[C@@H](O)[C@H](C)C(=O)[C@H](C)/C=C(\C)/C=C/C[C@@H](C)\C=C(/CC)\C=C\[C@@H]1OC(=O)C=C[C@@H]1C YACHGFWEQXFSBS-RJXCBBHPSA-N 0.000 description 1
- 229960003881 letrozole Drugs 0.000 description 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 1
- 229960001691 leucovorin Drugs 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 229960001614 levamisole Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000001459 lithography Methods 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 229940124302 mTOR inhibitor Drugs 0.000 description 1
- 238000009115 maintenance therapy Methods 0.000 description 1
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000003771 matrix metalloproteinase inhibitor Substances 0.000 description 1
- 229940121386 matrix metalloproteinase inhibitor Drugs 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- 229960002985 medroxyprogesterone acetate Drugs 0.000 description 1
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 1
- 229960004296 megestrol acetate Drugs 0.000 description 1
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 229960005558 mertansine Drugs 0.000 description 1
- ANZJBCHSOXCCRQ-FKUXLPTCSA-N mertansine Chemical compound CO[C@@H]([C@@]1(O)C[C@H](OC(=O)N1)[C@@H](C)[C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(=O)CCS)CC(=O)N1C)\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 ANZJBCHSOXCCRQ-FKUXLPTCSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- VKHAHZOOUSRJNA-GCNJZUOMSA-N mifepristone Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=CC=C(N(C)C)C=C1 VKHAHZOOUSRJNA-GCNJZUOMSA-N 0.000 description 1
- 229960003248 mifepristone Drugs 0.000 description 1
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 1
- 229960000350 mitotane Drugs 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 108010093470 monomethyl auristatin E Proteins 0.000 description 1
- HDZGCSFEDULWCS-UHFFFAOYSA-N monomethylhydrazine Chemical class CNN HDZGCSFEDULWCS-UHFFFAOYSA-N 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- AARXZCZYLAFQQU-UHFFFAOYSA-N motexafin gadolinium Chemical compound [Gd].CC(O)=O.CC(O)=O.C1=C([N-]2)C(CC)=C(CC)C2=CC(C(=C2C)CCCO)=NC2=CN=C2C=C(OCCOCCOCCOC)C(OCCOCCOCCOC)=CC2=NC=C2C(C)=C(CCCO)C1=N2 AARXZCZYLAFQQU-UHFFFAOYSA-N 0.000 description 1
- ZYQXEVJIFYIBHZ-UHFFFAOYSA-N n-[2-[4-[3-chloro-4-[3-(trifluoromethyl)phenoxy]anilino]pyrrolo[3,2-d]pyrimidin-5-yl]ethyl]-3-hydroxy-3-methylbutanamide Chemical compound C=12N(CCNC(=O)CC(C)(O)C)C=CC2=NC=NC=1NC(C=C1Cl)=CC=C1OC1=CC=CC(C(F)(F)F)=C1 ZYQXEVJIFYIBHZ-UHFFFAOYSA-N 0.000 description 1
- RDSACQWTXKSHJT-NSHDSACASA-N n-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)-6-methoxyphenyl]-1-[(2s)-2,3-dihydroxypropyl]cyclopropane-1-sulfonamide Chemical compound C1CC1(C[C@H](O)CO)S(=O)(=O)NC=1C(OC)=CC(F)=C(F)C=1NC1=CC=C(I)C=C1F RDSACQWTXKSHJT-NSHDSACASA-N 0.000 description 1
- QZGIWPZCWHMVQL-UIYAJPBUSA-N neocarzinostatin chromophore Chemical compound O1[C@H](C)[C@H](O)[C@H](O)[C@@H](NC)[C@H]1O[C@@H]1C/2=C/C#C[C@H]3O[C@@]3([C@@H]3OC(=O)OC3)C#CC\2=C[C@H]1OC(=O)C1=C(O)C=CC2=C(C)C=C(OC)C=C12 QZGIWPZCWHMVQL-UIYAJPBUSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- PCHKPVIQAHNQLW-CQSZACIVSA-N niraparib Chemical compound N1=C2C(C(=O)N)=CC=CC2=CN1C(C=C1)=CC=C1[C@@H]1CCCNC1 PCHKPVIQAHNQLW-CQSZACIVSA-N 0.000 description 1
- 229950011068 niraparib Drugs 0.000 description 1
- 229940125745 nitric oxide modulator Drugs 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 229960005419 nitrogen Drugs 0.000 description 1
- 102000027495 nuclear receptors type III Human genes 0.000 description 1
- 108091008732 nuclear receptors type III Proteins 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- FAQDUNYVKQKNLD-UHFFFAOYSA-N olaparib Chemical compound FC1=CC=C(CC2=C3[CH]C=CC=C3C(=O)N=N2)C=C1C(=O)N(CC1)CCN1C(=O)C1CC1 FAQDUNYVKQKNLD-UHFFFAOYSA-N 0.000 description 1
- 229960000572 olaparib Drugs 0.000 description 1
- 229960002230 omacetaxine mepesuccinate Drugs 0.000 description 1
- HYFHYPWGAURHIV-JFIAXGOJSA-N omacetaxine mepesuccinate Chemical compound C1=C2CCN3CCC[C@]43C=C(OC)[C@@H](OC(=O)[C@@](O)(CCCC(C)(C)O)CC(=O)OC)[C@H]4C2=CC2=C1OCO2 HYFHYPWGAURHIV-JFIAXGOJSA-N 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 229960001972 panitumumab Drugs 0.000 description 1
- 229950003440 panomifene Drugs 0.000 description 1
- 238000000059 patterning Methods 0.000 description 1
- 229950006299 pelitinib Drugs 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229960005079 pemetrexed Drugs 0.000 description 1
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 description 1
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
- 229960002340 pentostatin Drugs 0.000 description 1
- JGWRKYUXBBNENE-UHFFFAOYSA-N pexidartinib Chemical compound C1=NC(C(F)(F)F)=CC=C1CNC(N=C1)=CC=C1CC1=CNC2=NC=C(Cl)C=C12 JGWRKYUXBBNENE-UHFFFAOYSA-N 0.000 description 1
- 229950001457 pexidartinib Drugs 0.000 description 1
- 229940096826 phenylmercuric acetate Drugs 0.000 description 1
- VUXSPDNLYQTOSY-UHFFFAOYSA-N phenylmercuric borate Chemical compound OB(O)O[Hg]C1=CC=CC=C1 VUXSPDNLYQTOSY-UHFFFAOYSA-N 0.000 description 1
- 229960000247 phenylmercuric borate Drugs 0.000 description 1
- PDTFCHSETJBPTR-UHFFFAOYSA-N phenylmercuric nitrate Chemical compound [O-][N+](=O)O[Hg]C1=CC=CC=C1 PDTFCHSETJBPTR-UHFFFAOYSA-N 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 239000004038 photonic crystal Substances 0.000 description 1
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 description 1
- 229960002797 pitavastatin Drugs 0.000 description 1
- 239000002797 plasminogen activator inhibitor Substances 0.000 description 1
- 150000003058 platinum compounds Chemical class 0.000 description 1
- 229960003171 plicamycin Drugs 0.000 description 1
- YJGVMLPVUAXIQN-XVVDYKMHSA-N podophyllotoxin Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-XVVDYKMHSA-N 0.000 description 1
- 229960001237 podophyllotoxin Drugs 0.000 description 1
- YVCVYCSAAZQOJI-UHFFFAOYSA-N podophyllotoxin Natural products COC1=C(O)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YVCVYCSAAZQOJI-UHFFFAOYSA-N 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000003207 proteasome inhibitor Substances 0.000 description 1
- 239000003197 protein kinase B inhibitor Substances 0.000 description 1
- 239000003881 protein kinase C inhibitor Substances 0.000 description 1
- 239000003806 protein tyrosine phosphatase inhibitor Substances 0.000 description 1
- 239000000784 purine nucleoside phosphorylase inhibitor Substances 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- YUOCYTRGANSSRY-UHFFFAOYSA-N pyrrolo[2,3-i][1,2]benzodiazepine Chemical class C1=CN=NC2=C3C=CN=C3C=CC2=C1 YUOCYTRGANSSRY-UHFFFAOYSA-N 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011363 radioimmunotherapy Methods 0.000 description 1
- 229960004432 raltitrexed Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000002407 reforming Methods 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000000518 rheometry Methods 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- HMABYWSNWIZPAG-UHFFFAOYSA-N rucaparib Chemical compound C1=CC(CNC)=CC=C1C(N1)=C2CCNC(=O)C3=C2C1=CC(F)=C3 HMABYWSNWIZPAG-UHFFFAOYSA-N 0.000 description 1
- 229950004707 rucaparib Drugs 0.000 description 1
- DFJSJLGUIXFDJP-UHFFFAOYSA-N sapitinib Chemical compound C1CN(CC(=O)NC)CCC1OC(C(=CC1=NC=N2)OC)=CC1=C2NC1=CC=CC(Cl)=C1F DFJSJLGUIXFDJP-UHFFFAOYSA-N 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 229950010746 selumetinib Drugs 0.000 description 1
- 229960003440 semustine Drugs 0.000 description 1
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
- 229960002073 sertraline Drugs 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 229950006898 silmitasertib Drugs 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
- 229940100996 sodium bisulfate Drugs 0.000 description 1
- 229940001607 sodium bisulfite Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 229940001474 sodium thiosulfate Drugs 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000024642 stem cell division Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 108091007196 stromelysin Proteins 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 1
- 229960001796 sunitinib Drugs 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 239000003277 telomerase inhibitor Substances 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229960001712 testosterone propionate Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 229960003087 tioguanine Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
- 239000003558 transferase inhibitor Substances 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000002834 transmittance Methods 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 150000004654 triazenes Chemical class 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- YKUJZZHGTWVWHA-UHFFFAOYSA-N triptolide Natural products COC12CC3OC3(C(C)C)C(O)C14OC4CC5C6=C(CCC25C)C(=O)OC6 YKUJZZHGTWVWHA-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- GFNNBHLJANVSQV-UHFFFAOYSA-N tyrphostin AG 1478 Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1NC1=CC=CC(Cl)=C1 GFNNBHLJANVSQV-UHFFFAOYSA-N 0.000 description 1
- 229960001055 uracil mustard Drugs 0.000 description 1
- 150000003672 ureas Chemical class 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 229960000241 vandetanib Drugs 0.000 description 1
- UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 description 1
- 238000007740 vapor deposition Methods 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- 239000003021 water soluble solvent Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- QDLHCMPXEPAAMD-QAIWCSMKSA-N wortmannin Chemical compound C1([C@]2(C)C3=C(C4=O)OC=C3C(=O)O[C@@H]2COC)=C4[C@@H]2CCC(=O)[C@@]2(C)C[C@H]1OC(C)=O QDLHCMPXEPAAMD-QAIWCSMKSA-N 0.000 description 1
- QDLHCMPXEPAAMD-UHFFFAOYSA-N wortmannin Natural products COCC1OC(=O)C2=COC(C3=O)=C2C1(C)C1=C3C2CCC(=O)C2(C)CC1OC(C)=O QDLHCMPXEPAAMD-UHFFFAOYSA-N 0.000 description 1
- 239000003357 wound healing promoting agent Substances 0.000 description 1
- 229950009268 zinostatin Drugs 0.000 description 1
- 150000003952 β-lactams Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B30/00—Preparation of starch, degraded or non-chemically modified starch, amylose, or amylopectin
- C08B30/04—Extraction or purification
- C08B30/042—Extraction or purification from cereals or grains
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B30/00—Preparation of starch, degraded or non-chemically modified starch, amylose, or amylopectin
- C08B30/12—Degraded, destructured or non-chemically modified starch, e.g. mechanically, enzymatically or by irradiation; Bleaching of starch
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B31/00—Preparation of derivatives of starch
- C08B31/003—Crosslinking of starch
- C08B31/006—Crosslinking of derivatives of starch
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B31/00—Preparation of derivatives of starch
- C08B31/08—Ethers
- C08B31/12—Ethers having alkyl or cycloalkyl radicals substituted by heteroatoms, e.g. hydroxyalkyl or carboxyalkyl starch
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B31/00—Preparation of derivatives of starch
- C08B31/08—Ethers
- C08B31/12—Ethers having alkyl or cycloalkyl radicals substituted by heteroatoms, e.g. hydroxyalkyl or carboxyalkyl starch
- C08B31/125—Ethers having alkyl or cycloalkyl radicals substituted by heteroatoms, e.g. hydroxyalkyl or carboxyalkyl starch having a substituent containing at least one nitrogen atom, e.g. cationic starch
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L3/00—Compositions of starch, amylose or amylopectin or of their derivatives or degradation products
- C08L3/02—Starch; Degradation products thereof, e.g. dextrin
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L3/00—Compositions of starch, amylose or amylopectin or of their derivatives or degradation products
- C08L3/04—Starch derivatives, e.g. crosslinked derivatives
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L3/00—Compositions of starch, amylose or amylopectin or of their derivatives or degradation products
- C08L3/04—Starch derivatives, e.g. crosslinked derivatives
- C08L3/08—Ethers
Definitions
- patchy particles exhibit different properties than the isotropic particle body and produce materials with different characteristics such as selfassembly behavior.
- Patchy particles self-assemble through favorable free energy mechanisms such as electrostatic interactions and hydrophobic interactions and have found applications in fabricating photonic crystals, targeted delivery of drugs, as surfactants, and in electronics.
- These smart self-assembly particles have been made using numerous creative approaches to achieve the desired morphological engineering. For example, to prepare patchy particles, polystyrene and silica particles have been used to stabilize emulsions by residing on oil-water interface, and with the internal solvent being evaporated, droplets shrink and eventually form well-defined clusters.
- Particle lithography was also reported for patterning particle surface by utilizing the contact area between particles to avoid chemical adsorption to the surface. For example, by attaching the positively charged polystyrene particles to a negatively charged glass surface, a mask forms underneath the particles thus avoiding surface absorption to the negatively charged polystyrene sulfate.
- the approach of glancing-angle deposition which uses two-step vapor deposition on a monolayer of particles on a tape forming particles with two poles, was also adapted to manipulate surface morphology. This method allows the patches to be accurately positioned with a single patch as small as 3.7% of the total surface area of polystyrene beads. Besides approaches based on surface modification, bottom-up methods were also reported.
- the particles produced in this manner exhibited anisotropy not only on the surface but also inside the body, which used an electrohydrodynamic co-jetting capillary apparatus to produce a laminar flow of three immiscible streams carrying different polymers.
- the polymers precipitated as triphasic particles with three compartments formed with immiscible liquid, which provided the proof of concept for using a bottom-up method to prepare self-assembly patchy particles.
- Starch as a staple source of carbohydrates, is ubiquitous in foods, not only as a calorie source but also as clean-label additives, such as a thickener.
- the use of starch as a conventional thickener is based on gelatinization by hydrothermal treatment, which cleaves the hydrogen bonds in semi-crystalline region of starch thus providing space in the structure to absorb water. The swollen granules provide a larger volume which results in a stronger resistance to flow thus a higher viscosity and a thicker solution.
- amylose molecules are released from gelatinized granules due to the disrupted structure and are able to form a network as a settled gel upon cooling.
- a conventionally cooked starch slurry is susceptible to mechanical stress as the high shear of processing disintegrates the soft, swollen granules and the amylose gel network thus causing issues with food texture. It would be meaningful, therefore, to develop a new shear-reversible approach beyond swelling-based thickeners.
- compositions comprising the starch-based particles, food products comprising the starch- based particles, and methods of making the starch-based particles.
- the present disclosure provides starch-based particles.
- the starch- based particle may have a longest linear dimension (e.g., diameter) is 10-25 pm, including all 0.1 pm values and ranges therebetween.
- the starch-based particles have a core and a plurality of domains, wherein the plurality of domains are on an exterior surface of the starch-based particle, wherein the plurality of domains are a positively charged starch and the core is negatively charged or capable of being ionized to a negative charge.
- the starch-based particles may comprise one or more cationically-modified starch particles (e.g., cationically-modified amaranth starch particles) fused to an anionically- modified starch particle (e.g., anionically-modified corn starch particle), wherein at least a portion of a surface of the one or more cationically-modified starch particles (e.g., cationically-modified amaranth starch particles) is displayed on an exterior surface of the anionically-modified starch particle (e.g., anionically-modified corn starch particle).
- cationically-modified starch particles e.g., cationically-modified amaranth starch particles
- anionically-modified starch particle e.g., anionically-modified corn starch particle
- the anionically-modified starch particle may have one or more carboxylic acid groups or carboxylate groups, sulfonic groups, phosphate groups, partially deprotonated/protonated species thereof, or similar group.
- the anionic groups are carboxylic acid groups or carboxylate groups.
- the cationically-modified starch particles e.g., cationically-modified amaranth starch particles
- the cationically-modified starch particles e.g., cationically-modified amaranth starch particles
- compositions comprising one or more starch-based particles.
- the composition may be is a powder, tablet, paste, suspension, slurry, capsule, or gel.
- the composition may be added to a medium to thicken or otherwise increase the viscosity of the medium.
- the present disclosure provides methods of making the starch- based particles of the present disclosure.
- a method for making starch-based particles comprises: hydrating partially gelatinized starch (e.g., com starch) and a different starch (e.g., amaranth starch) with water; combining the partially gelatinized starch (e.g., partially gelatinized corn starch) and the different starch (e.g., the amaranth starch) at a ratio of 10: 1 to 50: 1 by weight (partially gelatinized starch (e.g., partially gelatinized corn starch) to different starch (e.g., amaranth starch)) to form a mixture; incubating the mixture at a temperature in the range of 25-50 °C for 5 to 15 minutes; centrifuging the mixture at 8,000-15,000 g for 5- 15 minutes (min); and removing a supernatant from the mixture, where the starch-based particles remains.
- the ratio of partially gelatinized starch and different starch e.g., the ratio of partially gelatinized starch and
- Figure 1 XRD curves of native starch, partially gelatinized starch, and fused patchy starch.
- FIG. 1 SEM images (a & b) of dry patchy particles prepared by incubation at 25 °C followed by centrifugation at 8000 g for 5 min, and their water suspension (c); SEM images (d & e) of dry patchy particles prepared by incubation at 50 °C followed by centrifugation at 15,000 g for 15 min, and their water suspension (f).
- the arrows indicate visible patches on surface of corn starch granules.
- the starches shown in Figure 2 are uncharged to demonstrate that the particle-particle association was not due to electrostatic interaction.
- the ratio between amaranth starch and com starch was 1 : 10.
- Figure 3 (a) FTIR spectra of native and anionic com starch, (b) FTIR spectra of native and cationic amaranth starch, (c). Zeta potentials of native and anionic corn starch, (d) Zeta potentials of native and cationic amaranth starch.
- Figure 4 Self-assembly of charged patchy starch in water (a); the waterholding capacity (b), rheological moduli (b), and viscosity (c) of uncharged, mixed charged, and patchy charged starch.
- the ratio between amaranth starch and com starch was 1 :50.
- Figure 5 (a) Processed images of 2% slurry of native com starch, (b) Distribution of native starch as individual particles, small aggregates, and large clumps, (c) Processed images of 2% slurry of patchy starch, (d) Distribution of patchy starch as individual particles, small aggregates, and large clumps. The ratio between amaranth starch and corn starch was 1 :50. [0020] Figure 6.
- Figure 7 Schematic showing the assembly of particles of the present disclosure.
- Figure 8. (a) SEM images of patchy starch prepared by incubation at 40 °C and centrifugation at 12,000 g. (b) The zoom-in image of a detached patch after starch fusion. [0023] Figure 9. Suspension of native com starch (a) and charged patchy starch (b). The scale bar is 50 pm.
- group refers to a chemical entity that is monovalent (i.e., has one terminus that can be covalently bonded to other chemical species), divalent, or polyvalent (i.e., has two or more termini that can be covalently bonded to other chemical species).
- group also includes radicals (e.g., monovalent and multivalent, such as, for example, divalent, trivalent, and the like, radicals).
- radicals e.g., monovalent and multivalent, such as, for example, divalent, trivalent, and the like, radicals.
- alkyl group refers to branched or unbranched, linear saturated hydrocarbon groups and/or cyclic hydrocarbon groups.
- alkyl groups include, but are not limited to, methyl groups, ethyl groups, propyl groups, butyl groups, isopropyl groups, tert-butyl groups, cyclopropyl groups, cyclopentyl groups, cyclohexyl groups, and the like.
- Alkyl groups are saturated groups, unless it is a cyclic group.
- an alkyl group is a Ci to C30 alkyl group, including all integer numbers of carbons and ranges of numbers of carbons therebetween (e.g., Ci, C2, C 3 , C 4 , C 5 , C6, C7, C 8 , C9, C10, Cll, C12, C13, C14, C15, C16, C17, C18, C19, C20, C21, C22, C23, C24, C25, C26, C27, C28, C29, and C30).
- the alkyl group may be unsubstituted or substituted with one or more substituents.
- substituents include, but are not limited to, halogens (-F, - Cl, -Br, and -I), aliphatic groups (e.g., alkyl groups, alkenyl groups, alkynyl groups, and the like), halogenated aliphatic groups (e.g., trifluoromethyl group), aryl groups, halogenated aryl groups, alkoxide groups, amine groups, nitro groups, carboxylate groups, carboxylic acids, ether groups, alcohol groups, alkyne groups (e.g., acetylenyl groups and the like), and the like, and combinations thereof.
- halogens -F, - Cl, -Br, and -I
- aliphatic groups e.g., alkyl groups, alkenyl groups, alkynyl groups, and the like
- halogenated aliphatic groups e.g., trifluoromethyl group
- treatment refers to reduction or delay in one or more symptoms or features associated with the presence of the particular condition being treated. Treatment does not necessarily mean complete cure and does not preclude relapse. Treatment may be carried out over a short period of time (days, weeks), or over a long period of time (months) or may be on a continuous basis (e.g., in the form of a maintenance therapy). Treatment may be continual or intermittent.
- terapéuticaally effective dose or amount as used herein is the amount sufficient to achieve, in a single or multiple doses, the intended purpose of treatment.
- an effective amount for effect wound healing is the amount sufficient to achieve one or more indicators of wound healing.
- the exact amount desired or required will vary depending on the mode of administration, patient specifics and the like. Appropriate effective amounts or the length of treatment can be determined by one of ordinary skill in the art (such as a clinician) with the benefit of the present disclosure.
- anionic groups and “anionically-modified corn starch particles” as used herein refers to groups that are either negatively charged or have the ability to be ionized such that the group has a negative charge.
- anionic groups or groups that would render a particle anionically modified include, but are not limited to, carboxylic acid groups or carboxylate groups, sulfonic groups, phosphate groups, or partially deprotonated/protonated species thereof.
- cationic groups and “cationically-modified corn starch particles” as used herein refers to groups that are either positively charged or have the ability to be ionized such that the group has a positively charge.
- cationic groups or groups that would render a particle cationically modified include, but are not limited to, alkylated ammonium groups or amine groups.
- alkylated ammonium groups include, but are not limited to, trimethylammonium groups or dimethylammonium groups.
- the present disclosure provides starch-based particles. Also provided are compositions comprising the starch-based particles, food products comprising the starch- based particles, and methods of making the starch-based particles.
- the present disclosure provides starch-based particles.
- the starch- based particle may have a longest linear dimension (e.g., diameter) is 10-25 pm, including all 0.1 pm values and ranges therebetween.
- the starch-based particles have a core and a plurality of domains, wherein the plurality of domains are on an exterior surface of the starch-based particle, wherein the plurality of domains are a positively charged starch and the core is negatively charged or capable of being ionized to a negative charge.
- the core may be negatively charged or capable of having a negative charge.
- the core may be functionalized with one or more carboxylic acid groups or carboxylate groups, sulfonic groups, phosphate groups, partially deprotonated/protonated species thereof, or similar group.
- the core has one or more carboxylic acid groups or carboxylate groups.
- the cores may comprise various starches.
- the starch may be a starch with a granular size of greater than or equal to 10 pm.
- starches include, but are not limited to, potato starch, wheat starch, corn starch, barley starch, pea starch, tapioca starch, and the like, and various combinations thereof.
- the starch when the starch is corn starch, the corn starch may have an amylose content of 0-75%, including all 0.1 values and ranges therebetween (e.g., 0%, 25%, 55%, or 70% (e.g., 55%)).
- the domains are positively charged or capable of having a positive charge.
- the domains may comprise one or more alkylated ammonium groups (e.g., trimethylammonium groups or one or more dimethylammonium groups).
- the domains comprise one or more trimethylammonium groups.
- the domains may comprise various starches.
- the starch has a granular size of less than 10 pm.
- examples of such starches include, but are not limited to, amaranth starch, riche starch, quinoa starch, taro starch, and the like, and various embodiments thereof.
- the domains comprise amaranth starch.
- the ratio of amaranth starch to com starch is 10:1 to 50: 1 and the ratio is a weight percent ratio, including all integer ratio values and ranges therebetween.
- the starch-based particles may comprise one or more cationically-modified starch particles (e.g., cationically-modified amaranth starch particles) fused to an anionically- modified starch particle (e.g., anionically-modified corn starch particle), wherein at least a portion of a surface of the one or more cationically-modified starch particles (e.g., cationically-modified amaranth starch particles) is displayed on an exterior surface of the anionically-modified starch particle (e.g., anionically-modified corn starch particle).
- cationically-modified starch particles e.g., cationically-modified amaranth starch particles
- anionically-modified starch particle e.g., anionically-modified corn starch particle
- the anionically-modified starch particle may have one or more carboxylic acid groups or carboxylate groups, sulfonic groups, phosphate groups, partially deprotonated/protonated species thereof, or similar group.
- the anionic groups are carboxylic acid groups or carboxylate groups.
- the cationically-modified starch particles e.g., cationically-modified amaranth starch particles
- the cationically-modified starch particles e.g., cationically-modified amaranth starch particles
- the anionically-modified starch particle (e.g., anionically-modified com starch particle) may have an amylose content of 0-75%, including all 0.1 values and ranges therebetween (e.g., 0%, 25%, 55%, or 70% (e.g., 55%)) prior to fusion to the one or more cationically-modified starch particles (e.g., cationically-modified amaranth starch particles).
- the ratio of cationically-modified starch to anionically-modified starch is 10: 1 to 50: 1 and the ratio is a weight percent ratio, including all integer ratio values and ranges therebetween.
- compositions comprising one or more starch-based particles.
- the composition may be is a powder, tablet, paste, suspension, slurry, capsule, or gel.
- the composition may be added to a medium to thicken or otherwise increase the viscosity of the medium.
- the starch-based particles trap water by self-association (e.g., aggregation) due to Coulombic interactions.
- a composition may comprise 0.01-99% by weight of the starched-based particles, including all 0.01 values and ranges therebetween (e.g., 1-40% by weight).
- a composition comprising the starch-based particles of the present disclosure has a viscosity higher than that of a composition comprising the same amount of unmodified or commercial cornstarch.
- the viscosity of the composition comprising the starch-based particles of the present disclosure at 10 s' 1 shear rate is > 1000-fold higher than the viscosity of a composition comprising unmodified or commercial cornstarch at the same 25% by weight concentration.
- a composition comprises starch-based particles that increase the viscosity or thicken relative to the same composition in the absence of the starch- based particles.
- the composition may be added to a medium for the purpose of increasing the viscosity or thicken and/or to texturize the medium.
- the starch-based particles may aggregate into clusters or aggregates comprising a plurality of starch-based particles.
- the aggregates may comprise at least 20 starch-based particles.
- at least 80% e.g., at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, or at least 95%) of the starch-based particles have formed aggregates comprising at least 20 starch-based particles.
- the aggregates may have an average size of 400 pm 2 or larger (e.g., 437 pm 2 ). Aggregation may be seen in compositions having a concentration of 2 weight percent starch-based particles.
- the composition may have desirable rheological properties.
- the composition comprising a plurality of the starch-based particles may have a storage modulus of >10 3 Pa at a frequency of 1 Hz at a concentration of 25% by weight the starch-based particles.
- the composition may be a slurry.
- the composition comprising a plurality of the starch-based particles may have a viscosity of > 10 Pa s at a shear rate of 0.1 s' 1 at a concentration of 25% by weight of the starch-based particles.
- the composition is a food additive.
- the food additive may be a thicken or texturizer.
- the composition e.g., food additive
- the composition may be added to or mixed into a food product for ingestion to thicken, texturize, or increase the viscosity of the food product.
- the amount of the composition added to the food product may be varied to adjust the desired viscosity of the food product.
- the composition e.g., food additive
- the viscosity or the texture of the food product is changed. For example, following addition of the composition, the viscosity of the food product is increased relative to its viscosity prior to the addition of the food additive.
- the composition may be suitable for delivery or vehicle for an agent (e.g., a pharmaceutical agent).
- agent e.g., a pharmaceutical agent
- the agent may be one or more small molecules and/or one or more biologically active components.
- compositions of the disclosure can comprise more than one pharmaceutical agent.
- a first composition comprising a compound of the disclosure and a first pharmaceutical agent can be separately prepared from a composition which comprises the same compound of the disclosure and a second pharmaceutical agent, and such preparations can be mixed to provide a two-pronged (or more) approach to achieving the desired prophylaxis or therapy in an individual.
- compositions of the disclosure can be prepared using mixed preparations of any of the compounds disclosed herein.
- the composition may comprise one or more small molecules.
- small molecules include, but are not limited to, antibiotics, antifungals, chemotherapy agents, antivirals, analgesics, anesthetics, antiparasitics, anti-septic agents, other wound healing agents, and the like, and combinations thereof.
- the composition may comprise one or more biologically active components.
- the biologically active component is a biologic.
- the biologically active component may be a protein, peptide, cDNA, siRNA, mRNA, monoclonal antibodies, or the like, or any combination thereof.
- agents include, but are not limited to, anti-androgens (e.g., Casodex, Flutamide, MDV3100, or ARN-509, Enzaluatide, apalutamide, darolutamid and abiraterone), MEK (e.g. MEK1, MEK2, or MEK1 and MEK2) inhibitors (e.g.
- anti-androgens e.g., Casodex, Flutamide, MDV3100, or ARN-509
- Enzaluatide e.g. MEK1, MEK2, or MEK1 and MEK2
- MEK e.g. MEK1, MEK2, or MEK1 and MEK2
- PTPN22 inhibitors e.g., PTPN1 inhibitors, PTPN2 inhibitors, CCR2 inhibitors, CXCR2 inhibitors, TORC1/TORC 2 inhibitors, PI-3K-AKT inhibitors, PARP inhibitors (e.g.
- cisplatin oxaloplatin, carboplatin
- anthracenedione e.g., mitoxantrone
- substituted urea e.g., hydroxyurea
- methyl hydrazine derivative e.g., procarbazine
- adrenocortical suppressant e.g., mitotane, aminoglutethimide
- epipodophyllotoxins e.g., etoposide
- enzymes e.g., L-asparaginase
- inhibitors of mitogen-activated protein kinase signaling e.g.
- wortmannin or LY294002 mTOR inhibitors
- antibodies e.g., rituxan
- MAP4K1 inhibitor e.g ZYF0033
- 5-aza-2'-deoxycytidine doxorubicin
- vincristine etoposide
- gemcitabine imatinib (Gleevec®)
- geldanamycin dasatinib, 17-N-Allylamino-17- Demethoxygeldanamycin (17-AAG), bortezomib, carfilzomide, trastuzumab, anastrozole
- angiogenesis inhibitors antiandrogen, antiestrogen; antisense oligonucleotides
- apoptosis gene modulators apoptosis regulators
- arginine deaminase BCR/ABL antagonists
- beta lactam derivatives bFGF inhibitor
- bicalutamide camptothecin derivatives
- gefitinib IressaTM
- erlotinib TarcevaTM
- cetuximab ErbituxTM
- lapatinib TykerbTM
- panitumumab VectibixTM
- vandetanib CaprelsaTM
- afatinib/BIBW2992 CI-1033/canertinib, neratinib/HKI-272, CP-724714, TAK-285, AST- 1306, ARRY334543, ARRY-380, AG-1478, dacomitinib/PF299804, OSI-420/desmethyl erlotinib, AZD8931, AEE788, pelitinib/EKB-569, CUDC-101, WZ8040, WZ4002, WZ3146, AG-490, XL647, PD153035, BMS-599626), sorafenib, imatinib, sunitinib, dasat
- tomaymycin carboplatin
- CC-1065 and CC-1065 analogs including amino-CBIs, nitrogen mustards (such as chlorambucil and melphalan), dolastatin and dolastatin analogs (including auristatins: e.g., monomethyl auristatin E), anthracycline antibiotics (such as doxorubicin, daunorubicin, etc.), duocarmycins and duocarmycin analogs, enediynes (such as neocarzinostatin and calicheamicins), leptomycin derivaties, maytansinoids and maytansinoid analogs (e.g.
- mertansine methotrexate, mitomycin C, taxoids, vinca alkaloids (such as vinblastine and vincristine), epothilones (e.g. epothilone B), camptothecin and its clinical analogs topotecan and irinotecan, or the like, vaccines (e.g., Bacillus Calmette-Guerin (BCG), CSF1R inhibitors (e.g., pexidartinib); class 3 receptor tyrosine kinases (RTKs), such as KIT, FLT3, and platelet-derived growth factor receptors PDGFRa and PDGFRp.
- BCG Bacillus Calmette-Guerin
- CSF1R inhibitors e.g., pexidartinib
- RTKs class 3 receptor tyrosine kinases
- compositions may be suitable for topical or transdermal application or oral administration.
- the compositions can be produced in any solid, liquid or semi-solid formulation, including creams, emulsions, anhydrous compositions, aqueous dispersions, oils, foams, lotions, gels, ointments, sprays or aerosols or any other form suitable via the skin or mucosal surface.
- the formulations can be incorporated into support materials that can be applied to a wound surface, such as, for example, bandages, gauzes, clothing, diapers, dressings, adhesive or non-adhesive patches, and the like.
- the formulations can also be incorporated into cosmetic materials, such as foundations, lipsticks, moisturizers, creams, masks, and the like.
- the composition may comprise one or more cosmetic components.
- cosmetic components include, but are not limited to, scented ingredients (e.g., essential oils and the like), exfoliating agents (e.g., salicylic acid and the like), lubricants (e.g., hyaluronic acid and the like), anti-cellulite agents (e.g., caffeine and the like), and the like, and various combinations thereof.
- scented ingredients e.g., essential oils and the like
- exfoliating agents e.g., salicylic acid and the like
- lubricants e.g., hyaluronic acid and the like
- anti-cellulite agents e.g., caffeine and the like
- additive ingredients may also optionally be included in the cosmetic compositions.
- Non-limiting examples include water, non-volatile fatty substances, inorganic pigments, soft focus particles/powders, fragrances, preservatives, coalescents, wetting agents, water-soluble solvents, emollients, suspending agents, surfactants, actives, and the like.
- One unique feature of the cosmetic compositions is that they may include water (aqueous compositions) or may be free of water (anhydrous compositions).
- compositions may include pharmaceutically or cosmetically acceptable excipients, such as, buffering agents, antioxidants, preservatives, colorants, carriers, diluents, adjuvants, salts, and the like.
- Suitable water soluble buffering agents include carbonates, phosphates, bicarbonates, citrates, borates, acetates, succinates and the like, such as sodium phosphate, citrate, borate, acetate, bicarbonate, carbonate and the like. These agents are advantageously present in amounts sufficient to maintain a pH of the system about 6, such as between about 7 to about 10 and more preferably about 7 to about 9.
- Suitable water soluble preservatives include sodium bisulfite, sodium bisulfate, sodium thiosulfate, ascorbate, benzalkonium chloride, chlorobutanol, thimerosal, phenylmercuric acetate, phenylmercuric borate, phenylmercuric nitrate, parabens, methylparaben, polyvinyl alcohol, benzyl alcohol, phenylethanol and the like and mixtures thereof.
- the excipients may be present in amounts of from 0.001 to about 5% by weight, such as, for example, 0.01 to about 2% by weight.
- Pharmaceutical composition ingredients and preparation can be carried out by standard pharmaceutical formulation techniques such as those disclosed in Remington: The Science and Practice of Pharmacy (2012) 22nd Edition, Philadelphia, PA. Lippincott Williams & Wilkins.
- the present disclosure provides food products.
- the food product may comprise the starch-based particles of the present disclosure or a composition comprising the starch-based particles of the present disclosures.
- Various food products may comprise the starch-based particles of the present disclosure or a composition comprising the starch-based particles of the present disclosures.
- Non-limiting examples of food products include sauces, soups, fillings, custards, puddings, desserts, dressings, and the like.
- Other food products are known in the art and are within the scope of the present disclosure.
- the food products are suitable for ingestion may humans and/or animals.
- the present disclosure provides methods of making the starch- based particles of the present disclosure.
- a method for making starch-based particles comprises: hydrating partially gelatinized starch (e.g., com starch) and a different starch (e.g., amaranth starch) with water; combining the partially gelatinized starch (e.g., partially gelatinized corn starch) and the different starch (e.g., the amaranth starch) at a ratio of 10: 1 to 50: 1 by weight (partially gelatinized starch (e.g., partially gelatinized corn starch) to different starch (e.g., amaranth starch)) to form a mixture; incubating the mixture at a temperature in the range of 25-50 °C for 5 to 15 minutes; centrifuging the mixture at 8,000-15,000 g for 5- 15 minutes (min); and removing a supernatant from the mixture, where the starch-based particles remains.
- the ratio of partially gelatinized starch and different starch e.g., the ratio of partially gelatinized starch and
- the partially gelatinized starch (e.g., the partially gelatinized corn starch) is modified such that it comprises one or more anionic groups (e.g., one or more carboxylic acid groups or carboxylate groups, sulfonic groups, phosphate groups, or partially deprotonated/protonated species thereof).
- the one or more anionic groups are carboxylate groups.
- the partially gelatinized starch may be com starch, potato starch, wheat starch, barley starch, pea starch, tapioca starch, or the like, or various combinations thereof.
- the partially gelatinized starch is corn starch.
- the different starch (e.g., starch other than com starch) (e.g., amaranth starch) may be modified such that is comprises one or more cationic groups (e.g., quaternary amines, such as, for example, alkylated amines).
- one or more cationic groups are one or more trimethylammonium groups or one or more dimethylammonium groups.
- the one or more cationic groups are one or more trimethylammonium groups.
- the starch is amaranth starch, rice starch, quinoa starch, taro starch, or the like, or various combinations thereof.
- the starch is amaranth starch.
- the partially gelatinized starch e.g., partially gelatinized corn starch
- the different starch e.g., amaranth starch
- the steps of the method described in the various embodiments and examples disclosed herein are sufficient to carry out the methods of the present disclosure.
- the method consists essentially of a combination of the steps of the methods disclosed herein.
- the method consists of such steps.
- a starch-based particle having a core and a plurality of domains, wherein the plurality of domains are on an exterior surface of the starch-based particle, wherein the plurality of domains are a positively charged starch (e.g., a positively charged amaranth starch) and the core is negatively charged or capable of being ionized to a negative charge.
- a positively charged starch e.g., a positively charged amaranth starch
- Statement 3 A starch-based particle according to Statement 1 or Statement 2, wherein the core has one or more carboxylic acid groups or carboxylate groups.
- Statement 4. A starch-based particle according to any one of the preceding Statements, wherein the domains have one or more trimethylammonium groups or one or more dimethylammonium groups.
- the core e.g., corn starch
- Statement 12 A starch-based particle according to any one of Statements 9-11, wherein the corn starch has an amylose content of 55%.
- a starch-based particle comprising one or more cationically-modified starch particles (e.g., cationically-modified amaranth starch particles) fused to an anionically- modified starch particle (e.g., anionically-modified corn starch particle), wherein at least a portion of a surface of the one or more cationically-modified starch particles (e.g., cationically-modified amaranth starch particles) is displayed on an exterior surface of the anionically-modified starch particle (e.g., anionically-modified corn starch particle).
- Statement 15 A starch-based particle according to Statement 14, wherein at least a portion of the cationically-modified starch particles comprise amaranth starch, rice starch, quinoa starch, taro starch, or the like, or various combinations thereof.
- a starch-based particle according to Statement 18, wherein the anionically- modified starch particle e.g., anionically-modified corn starch particle
- the anionically-modified starch particle has one or more carboxylic acid groups or carboxylate groups, sulfonic groups, phosphate groups, or partially deprotonated/protonated species thereof.
- the anionically-modified starch particle e.g., anionically-modified corn starch particle
- Statement 20 A starch-based particle according to any one of Statements 14-19, wherein the cationically-modified starch particles (e.g., cationically-modified amaranth starch particles) have one or more trimethylammonium groups or one or more dimethylammonium groups.
- the cationically-modified starch particles e.g., cationically-modified amaranth starch particles
- the corn starch has an amylose content of 0%, 25%, 55%, or 70% prior to fusion to the one or more cationically-modified starch particles (e.g., cationically-modified amaranth starch particles).
- the anionically-modified starch particle (e.g., anionically- modified corn starch particle) has an amylose content of 55% prior to fusion to the one or more cationically-modified starch particles (e.g., cationically-modified amaranth starch particles).
- Statement 22 A starch-based particle according to any one of Statements 14-21, wherein the ratio of cationically-modified starch to anionically-modified starch (e.g., cationically- modified amaranth starch to anionically-modified com starch) is 10: 1 to 50: 1 and the ratio is a weight percent ratio.
- Statement 24 A composition comprising one or more starch-based particles according to any one of the preceding Statements.
- Statement 25 A composition according to Statement 24, wherein the composition is a powder, tablet, paste, suspension, slurry, capsule, or gel.
- Statement 26 A composition according to Statement 24 or Statement 25, comprising one or more aggregates comprising the one or more starch-based particles according to any one of Statements 1-23.
- Statement 27 A composition according to Statement 26, wherein a portion of the aggregates individually comprise at least 20 starch-based particles.
- Statement 28 A composition according to Statement 26 or Statement 27, wherein at least 80% of the starch-based particles have formed aggregates comprising at least 20 starch-based particles.
- Statement 29 A composition according to any one of Statements 24-28, wherein the aggregates have an average size of 400 pm 2 or larger. This size is an area of aggregation from image processing during microscopy.
- Statement 30 A composition according to any one of Statements 24-29, wherein the composition has a storage modulus of >10 3 Pa at a frequency of 1 Hz.
- Statement 31 A composition according to any one of Statements 24-30, wherein the composition is 25% by weight the starch-based particles.
- Statement 32 A composition according to any one of Statements 24-31, wherein the composition is a food additive.
- Statement 33 A composition according to any one of Statements 24-32, wherein the composition is a thickener or a texturizer.
- Statement 34 A composition according to any one of Statements 24-33, wherein the one or more starch-based particles are present at a concentration of 1-40% by weight.
- Statement 35 A composition according to any one of Statements 24-31, 33, or 34, further comprising one or more small molecules and/or biologically active component.
- Statement 36 A composition according to Statement 35, wherein the one or more small molecules are chosen from antibiotics, antifungals, chemotherapy agents, antivirals, analgesics, anesthetics, and the like, and combinations thereof.
- Statement 37 A composition according to Statement 35, wherein the biologically active component is a biologic.
- Statement 38 A composition according to Statement 35 or Statement 37, wherein the biologically active component is a protein, peptide, cDNA, siRNA, mRNA, monoclonal antibodies, or the like, or any combination thereof.
- composition according to Statement 39 wherein the one or more cosmetic components are chosen from scented ingredients (e.g., essential oils and the like), exfoliating agents (e.g., salicylic acid and the like), lubricants (e.g., hyaluronic acid and the like), anticellulite agents (e.g., caffeine and the like), and the like, and various combinations thereof.
- scented ingredients e.g., essential oils and the like
- exfoliating agents e.g., salicylic acid and the like
- lubricants e.g., hyaluronic acid and the like
- anticellulite agents e.g., caffeine and the like
- Statement 41 A food product comprising the one or more starch-based particles according to any one of Statements 1-23 or the composition according to any one of Statements 24-33.
- Statement 42 A food product according to Statement 41, wherein the food product is a sauce, a soup, a filling, a custard, a pudding, a dessert, a dressing, or the like.
- Statement 43 A method for making starch-based particles according to any one of Statements 1-23, comprising: hydrating partially gelatinized starch (e.g., partially gelatinized corn starch) and a different starch (e.g., amaranth starch) with water; combining the partially gelatinized corn starch and amaranth starch at a ratio of 10:1 to 50:1 by weight (partially gelatinized corn starch to amaranth starch) to form a mixture; incubating the mixture at a temperature in the range of 25-50 °C for 5 to 15 minutes; centrifuging the mixture at 8, GOO- 15, 000 g for 5 to 15 min; and removing a supernatant from the mixture, wherein the starch- based particles remains.
- Statement 44 A method according to Statement 43, wherein at least a portion of the different starch comprises amaranth starch, rice starch, quinoa starch, taro starch, or the like, or various combinations thereof.
- Statement 45 A method according to Statement 43 or Statement 44, wherein at least a portion of the cationically-modified starch particles comprise amaranth starch.
- Statement 46 A method according to any one of Statements 43-45, wherein the partially gelatinized starch comprises corn starch, potato starch, wheat starch, barley starch, pea starch, tapioca starch, or the like, or various combinations thereof.
- Statement 47 A method according to any one of Statements 43-46, wherein the partially gelatinized starch comprises corn starch.
- Statement 48 A method according to any one of Statements 43-47, wherein the ratio of partially gelatinized starch (e.g., partially gelatinized corn starch) and different starch (e.g., amaranth starch) is 50: 1 by weight.
- partially gelatinized starch e.g., partially gelatinized corn starch
- different starch e.g., amaranth starch
- Statement 49 A method according to any one of Statements 43-48, wherein the partially gelatinized starch (e.g., partially gelatinized com starch) is modified such that it comprises one or more anionic groups.
- the partially gelatinized starch e.g., partially gelatinized com starch
- Statement 50 A method according to Statement 49, wherein the one or more anionic groups are carboxylic acid groups or carboxylate groups, sulfonic groups, phosphate groups, or partially deprotonated/protonated species thereof.
- Statement 51 A method according to Statement 49 or Statement 50, wherein the one or more anionic groups are carboxylate groups.
- Statement 52 A method according to any one of Statements 43-51, wherein the different starch (e.g., amaranth starch) is modified such that is comprises one or more cationic groups.
- the different starch e.g., amaranth starch
- Statement 53 A method according to Statement 52, wherein the one or more cationic groups are quaternary amines.
- Statement 54 A method according to Statement 53, wherein the quaternary amines are alkylated ammonium groups.
- Statement 55 A method according to Statement 54, wherein the alkylated ammonium groups are trimethylammonium groups or dimethylammonium groups.
- Statement 56 A method according to any one of Statement 54 or Statement 55, wherein the alkylated ammonium group is a trimethylammonium group.
- Statement 57 A method according to any one of Statements 43-56, wherein the partially gelatinized starch (e.g., partially gelatinized starch) and different starch (e.g., amaranth starch) are hydrated with water at a ratio of 1 :5 (starch to water) by weight.
- partially gelatinized starch e.g., partially gelatinized starch
- different starch e.g., amaranth starch
- the granular size of starch depends on the botanical sources and can vary from 1 pm (amaranth starch) to over 50 pm (potato starch).
- a possible approach to prepare a fused starch particle is partial gelatinization. Alcohols precipitate starch from aqueous solutions and have been used to limit the degree of gelatinization. With the hydrothermal treatment in aqueous alcohols, the granules would still maintain the intact shape, even though the double helices of starch dissociate. Alcohols have also been shown to enter the single helix of amylose forming metastable inclusion complexes.
- amaranth starch was extracted from amaranth flour by a previously published method. Specifically, amaranth flour (100 g) was blended with 500 mL of a 0.15 % w/v NaOH solution at ambient temperature for 60 min. The mixture then was sieved (53 pm mesh opening, VWR, IL, USA) with a laboratory shaker (Derrick Mfg. Co., Buffalo, NY, USA). The fine starch granules dispersed in liquid passed through the sieve and the remaining solid was redispersed in fresh NaOH solution (100 mL) followed by another 10 min of mixing.
- the extract was filtered using the sieve with 53 pm mesh opening and combined with the first batch, which was then centrifuged at 3,000 g for 20 min. The supernatant was discarded, and the top brown protein layer was removed using spatula. The sediments were redispersed in deionized water with pH adjusted to 6.0 ⁇ 0.1 using 1 M HC1. The yellow protein layer that formed after pH adjustment was removed again to purify the starch. The remaining lower white layer was freeze-dried and ground into powders. The isolated starch contained 2.4% protein and 2.2% fat.
- the starch was partially gelatinized by hydrothermal processing in alcohol as previously published. Specifically, 100 g of native starch was mixed with 500 mL of aqueous ethanol (50% v/v for amaranth starch and 30% v/v for corn starch). The starch-in-solvent suspensions were heated at 80 °C for 30 min. After thermal incubation, 100 mL ethanol was added to the slurry, and the starch was then filtered (Grade 1, Waterman). The filtered starch was washed three times with ethyl alcohol, and the solvent was removed in an oven at 80 °C for 8 h to remove residuals. The dry starch was ground with a homogenizer (Oster 2095357, FL, USA) for 2 min, and the powder was sieved (#50 mesh) then stored for future use.
- aqueous ethanol 50% v/v for amaranth starch and 30% v/v for corn starch.
- the starch-in-solvent suspensions were
- the washed starch was subsequently centrifuged at 3,000 g for 3 min and then washed with additional 80% ethanol and centrifuged twice more.
- the starch was then dispersed in 200 mL DI water and 0.1 M HC1 was used to adjust the pH to 7 to neutralize residual NaOH.
- the neutralized starch was centrifuged (3000 g for 3 min) and washed twice to remove residual salts.
- the starch pellet was freeze-dried for further use.
- amaranth starch was positively charged by a modification method previously established. Specifically, we dispersed 1 g amaranth starch in 2 mL of water containing 1.91 g of ETMAC. The pH of the slurry was adjusted to 10.5 using 0.1 M NaOH. The mixture was then stirred at room temperature for 24 hours after which, the slurry was centrifuged (5000 g for 3 min) and the sediment was further washed with DI water twice, and the collected starch was further washed using ethanol. The starch was dried in a ventilated oven at room temperature.
- the swollen granules interpenetrated the other granules while being centrifuged, and the polymer chains tangled together. After centrifuging, the clear supernatant was decanted, and the starch was dried in a ventilated oven at room temperature for 96 h and then stored at 4 °C for further characterization.
- FTIR Attenuated total reflectance-Fourier transform infrared spectroscopy
- ATR-FTIR Affinity- IS, Shimadzu
- Samples were measured from 400 to 4000 cm' 1 in transmittance mode with 2 cm' 1 resolution and 128 scans.
- X-ray diffractometry X-ray diffractometry
- MA Bruker D8 Advance ECO powder diffractometer
- MA Bruker D8 Advance ECO powder diffractometer
- the samples were examined for the angles 29 between 5° and 40°.
- Scanning electron microscopy SEM. Samples were coated with Au-Pd using a sputter coater (Denton Desk V, NJ, USA). The coated samples were examined with an SEM (Zeiss Gemini 500, Jena, Germany). Objects were scanned with 1 keV and imaged by a high efficiency secondary electron detector with a 20.0 pm aperture.
- the hydrogen bonding in starch can be disrupted by thermal processing at temperatures higher than its gelatinization temperature in aqueous alcohol. Ethanol as the precipitant of starch is able to inhibit amylose leaching and the original granular shape of the starch is maintained. This partial gelatinization allows the starch to absorb the water and the swollen starch becomes softer, less crystalline.
- the XRD curves ( Figure 1) indicate that native starch exhibits typical B-type crystals with peaks at 5.5°, 15°, 17°, 20°, and 22.5°, which were in agreement with the data reported previously. After partially gelatinized starch were produced by hydrothermal processing in aqueous alcohol, however, those peaks diminished suggesting the dissociation of the hydrogen bonding between polymer chains and thus lower crystallinity.
- the partially gelatinized starch undergoes retrogradation, which refers to the spontaneous process by which disordered polymer chains recrystallize.
- the patchy starch after dehydration showed recovered crystallization compared with the partially gelatinized starch ( Figure 1).
- water evaporates allowing the hydroxyl groups on the polymer chains to get close enough to reform the hydrogen bonds.
- retrogradation is usually considered an undesirable process for food products causing bread staling, it can also be utilized as an approach to construct patchy particles.
- starch-based patchy particles The principle behind fabricating starch-based patchy particles is attributed to the partially gelatinized and hydrated starch granules.
- the softening of the starch granule is an indication of the increased degree of freedom of polymer chains and then the strong centrifugation helps them penetrate into the other granules.
- the polymer chains tangle together, and during the processing of dehydration and refrigeration, can recrystallize through hydrogen bonding. This retrogradation allows multiple particles to fuse as a single particle.
- the intense treatment enhanced the connection between the patches and the primary granule, it was found that after treatment there was a small amount of amaranth starch granules extremely gelatinized, which was not entirely unexpected due to the elevated incubation temperature.
- the carboxyl modification gives the starch a negative charge which we observe at -19.1 mV at neutral pH ( Figure 3c).
- the FTIR spectra shows that the native amaranth starch exhibits a band at 1750 cm' 1 ( Figure 3b) suggesting the presence of carbonyl groups, which can be attributed to the minor protein content (-2.5%) after extraction from flour.
- the negative zeta-potential (-19.4 mV) of the native amaranth starch was also rendered by the minor protein content (Figure 3d).
- the amaranth starch had a zeta-potential of +19.6 mV ( Figure 3d) and the carbonyl band on FTIR spectra was diminished, confirming that the ETMAC reacted with the carboxyl group of the proteins. Additionally, the new band at 1300 cm' 1 can be attributed to the C-N stretch indicating the presence of the trimethyl ammonium group. [0096] The charged starches were physically fused together and exhibited a negatively charged core and positively charged patches on the surface.
- the present disclosure provides a facile method for preparing patchy particles using two different sized starches as food-grade ingredients, and it is the first time a study of heterogeneous surface model has been extended to biodegradable natural materials. After partial gelatinization, the swollen starch granules were centrifuged and dehydrated, which yielded a corona-shaped patchy structure where the smaller amaranth starch grafted onto the larger corn starch particles. Further the patchy starch exhibited an anionic core and cationic patches after charge modification. The patchy particles also showed higher water-holding capacity as the interparticle interactions allowed water to be trapped in pockets of the superstructure formed by granules.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Polymers & Plastics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Inorganic Chemistry (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Cosmetics (AREA)
- General Preparation And Processing Of Foods (AREA)
- Medicinal Preparation (AREA)
Abstract
The present disclosure provides starch-based particles. Also provided are compositions of the starch-based particles, cosmetics containing the starch-based particles, pharmaceutical compositions containing the starch-based particles, food products containing the starch-based particles, and methods of making the starch-based particles.
Description
CHARGED STARCH-BASED PARTICLES
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application claims priority to U.S. Provisional Application No. 63/330,470, filed on April 13, 2022, the disclosure of which is incorporated herein by reference.
BACKGROUND OF THE DISCLOSURE
[0002] The research area of patchy particles, surfaces with non-homogenous patterns, has gained considerable interest recently. The patches exhibit different properties than the isotropic particle body and produce materials with different characteristics such as selfassembly behavior. Patchy particles self-assemble through favorable free energy mechanisms such as electrostatic interactions and hydrophobic interactions and have found applications in fabricating photonic crystals, targeted delivery of drugs, as surfactants, and in electronics. [0003] These smart self-assembly particles have been made using numerous creative approaches to achieve the desired morphological engineering. For example, to prepare patchy particles, polystyrene and silica particles have been used to stabilize emulsions by residing on oil-water interface, and with the internal solvent being evaporated, droplets shrink and eventually form well-defined clusters. Particle lithography was also reported for patterning particle surface by utilizing the contact area between particles to avoid chemical adsorption to the surface. For example, by attaching the positively charged polystyrene particles to a negatively charged glass surface, a mask forms underneath the particles thus avoiding surface absorption to the negatively charged polystyrene sulfate. The approach of glancing-angle deposition, which uses two-step vapor deposition on a monolayer of particles on a tape forming particles with two poles, was also adapted to manipulate surface morphology. This method allows the patches to be accurately positioned with a single patch as small as 3.7% of the total surface area of polystyrene beads. Besides approaches based on surface modification, bottom-up methods were also reported. The particles produced in this manner exhibited anisotropy not only on the surface but also inside the body, which used an electrohydrodynamic co-jetting capillary apparatus to produce a laminar flow of three immiscible streams carrying different polymers. After the solvent evaporated the polymers precipitated as triphasic particles with three compartments formed with immiscible liquid, which provided the proof of concept for using a bottom-up method to prepare self-assembly patchy particles.
[0004] Despite the creativity of the methods for fabricating patchy particles, the majority of them bear the limitation of laboratory production scale. That is, the cost of producing these materials is too high to be practically scaled up for industrial purposes. Future research needs to explore additional approaches that can prepare patchy particles economically. Another gap related to patchy particles is that the materials reported in the literature are made with hazardous organic chemicals, which suggests that future studies could explore alternatives based on ingredients that are biodegradable and food-grade. [0005] Starch, as a staple source of carbohydrates, is ubiquitous in foods, not only as a calorie source but also as clean-label additives, such as a thickener. The use of starch as a conventional thickener is based on gelatinization by hydrothermal treatment, which cleaves the hydrogen bonds in semi-crystalline region of starch thus providing space in the structure to absorb water. The swollen granules provide a larger volume which results in a stronger resistance to flow thus a higher viscosity and a thicker solution. Meanwhile, amylose molecules are released from gelatinized granules due to the disrupted structure and are able to form a network as a settled gel upon cooling. However, a conventionally cooked starch slurry is susceptible to mechanical stress as the high shear of processing disintegrates the soft, swollen granules and the amylose gel network thus causing issues with food texture. It would be meaningful, therefore, to develop a new shear-reversible approach beyond swelling-based thickeners.
[0006] Instead of trapping water in the swollen granules, a possible alternative to enhance thickening is to retain the water molecules between starch particles. To achieve this, patchy particles would be a potential platform to render the starch granules with selfassembly features. To the best of our knowledge, starch has not been used to fabricate patchy particles though it is a food-grade, affordable, and naturally available ingredient. There are more than 20 different modification methods for starch geared toward improving starch functionality, but none of the conventional approaches has been able to produce starch granules showing a heterogeneous surface with patches providing different properties compared with the native particle body. Previous work from our lab successfully fabricated starch-based Janus particles with two faces using a 2D-masking method. The Janus particles exhibited hydrophobic properties on the hemisphere esterified by octenyl succinic anhydride and allowed the starch granules to assemble into worm-like super micelles.
BRIEF SUMMARY OF THE DISCLOSURE
[0007] The present disclosure provides starch-based particles. Also provided are compositions comprising the starch-based particles, food products comprising the starch- based particles, and methods of making the starch-based particles.
[0008] In an aspect, the present disclosure provides starch-based particles. The starch- based particle may have a longest linear dimension (e.g., diameter) is 10-25 pm, including all 0.1 pm values and ranges therebetween.
[0009] In an embodiment, the starch-based particles have a core and a plurality of domains, wherein the plurality of domains are on an exterior surface of the starch-based particle, wherein the plurality of domains are a positively charged starch and the core is negatively charged or capable of being ionized to a negative charge.
[0010] The starch-based particles may comprise one or more cationically-modified starch particles (e.g., cationically-modified amaranth starch particles) fused to an anionically- modified starch particle (e.g., anionically-modified corn starch particle), wherein at least a portion of a surface of the one or more cationically-modified starch particles (e.g., cationically-modified amaranth starch particles) is displayed on an exterior surface of the anionically-modified starch particle (e.g., anionically-modified corn starch particle). The anionically-modified starch particle (e.g., anionically-modified corn starch particle) may have one or more carboxylic acid groups or carboxylate groups, sulfonic groups, phosphate groups, partially deprotonated/protonated species thereof, or similar group. In various embodiments, the anionic groups are carboxylic acid groups or carboxylate groups. The cationically-modified starch particles (e.g., cationically-modified amaranth starch particles) may have one or more alkylated ammonium groups (e.g., trimethylammonium groups or one or more dimethylammonium groups or one or more dimethylammonium groups). In various embodiments, the cationically-modified starch particles (e.g., cationically-modified amaranth starch particles) have one or more trimethylammonium groups.
[0011] In an aspect, the present disclosure provide compositions comprising one or more starch-based particles. The composition may be is a powder, tablet, paste, suspension, slurry, capsule, or gel. In various embodiments, the composition may be added to a medium to thicken or otherwise increase the viscosity of the medium.
[0012] In an aspect, the present disclosure provides methods of making the starch- based particles of the present disclosure.
[0013] In various embodiments, a method for making starch-based particles, comprises: hydrating partially gelatinized starch (e.g., com starch) and a different starch (e.g.,
amaranth starch) with water; combining the partially gelatinized starch (e.g., partially gelatinized corn starch) and the different starch (e.g., the amaranth starch) at a ratio of 10: 1 to 50: 1 by weight (partially gelatinized starch (e.g., partially gelatinized corn starch) to different starch (e.g., amaranth starch)) to form a mixture; incubating the mixture at a temperature in the range of 25-50 °C for 5 to 15 minutes; centrifuging the mixture at 8,000-15,000 g for 5- 15 minutes (min); and removing a supernatant from the mixture, where the starch-based particles remains. In various embodiments, the ratio of partially gelatinized starch and different starch (e.g., the partially gelatinized corn starch to amaranth starch) is 50: 1 by weight, including all ratio values and ranges therebetween.
BRIEF DESCRIPTION OF THE FIGURES
[0014] For a fuller understanding of the nature and objects of the disclosure, reference should be made to the following detailed description taken in conjunction with the accompanying figures.
[0015] Figure 1. XRD curves of native starch, partially gelatinized starch, and fused patchy starch.
[0016] Figure 2. SEM images (a & b) of dry patchy particles prepared by incubation at 25 °C followed by centrifugation at 8000 g for 5 min, and their water suspension (c); SEM images (d & e) of dry patchy particles prepared by incubation at 50 °C followed by centrifugation at 15,000 g for 15 min, and their water suspension (f). The arrows indicate visible patches on surface of corn starch granules. The starches shown in Figure 2 are uncharged to demonstrate that the particle-particle association was not due to electrostatic interaction. The ratio between amaranth starch and com starch was 1 : 10.
[0017] Figure 3. (a) FTIR spectra of native and anionic com starch, (b) FTIR spectra of native and cationic amaranth starch, (c). Zeta potentials of native and anionic corn starch, (d) Zeta potentials of native and cationic amaranth starch.
[0018] Figure 4. Self-assembly of charged patchy starch in water (a); the waterholding capacity (b), rheological moduli (b), and viscosity (c) of uncharged, mixed charged, and patchy charged starch. The ratio between amaranth starch and com starch was 1 :50.
[0019] Figure 5. (a) Processed images of 2% slurry of native com starch, (b) Distribution of native starch as individual particles, small aggregates, and large clumps, (c) Processed images of 2% slurry of patchy starch, (d) Distribution of patchy starch as individual particles, small aggregates, and large clumps. The ratio between amaranth starch and corn starch was 1 :50.
[0020] Figure 6. (a) Storage modulus and loss modulus of gelatinized slurry containing 10% uncharged, mixed charged, and patchy starch, (b) Viscosity of gelatinized slurry containing 10% uncharged, mixed charged, and patchy starch, (c) Viscosity of sheared gelatinized slurry containing 10% uncharged, mixed charged, and patchy starch.
[0021] Figure 7. Schematic showing the assembly of particles of the present disclosure.
[0022] Figure 8. (a) SEM images of patchy starch prepared by incubation at 40 °C and centrifugation at 12,000 g. (b) The zoom-in image of a detached patch after starch fusion. [0023] Figure 9. Suspension of native com starch (a) and charged patchy starch (b). The scale bar is 50 pm.
DETAILED DESCRIPTION OF THE DISCLOSURE
[0024] Although claimed subject matter will be described in terms of certain embodiments, other embodiments, including embodiments that do not provide all of the benefits and features set forth herein, are also within the scope of this disclosure. Various structural, logical, and process step changes may be made without departing from the scope of the disclosure.
[0025] Where a range of values is provided in this disclosure, it should be understood that each intervening value, to the tenth of the unit of the lower limit between the upper and lower limit of that range, and any other intervening value in that stated range is encompassed within the disclosure, unless clearly indicated otherwise. The upper and lower limits of these smaller ranges may independently be included in the smaller ranges encompassed within the disclosure.
[0026] As used in this disclosure, the singular forms include the plural forms and vice versa unless the context clearly indicates otherwise.
[0027] As used herein, unless otherwise stated, the term “group” refers to a chemical entity that is monovalent (i.e., has one terminus that can be covalently bonded to other chemical species), divalent, or polyvalent (i.e., has two or more termini that can be covalently bonded to other chemical species). The term “group” also includes radicals (e.g., monovalent and multivalent, such as, for example, divalent, trivalent, and the like, radicals). Illustrative examples of groups include:
[0028] As used herein, unless otherwise indicated, the term “alkyl group” refers to branched or unbranched, linear saturated hydrocarbon groups and/or cyclic hydrocarbon groups. Examples of alkyl groups include, but are not limited to, methyl groups, ethyl groups, propyl groups, butyl groups, isopropyl groups, tert-butyl groups, cyclopropyl groups, cyclopentyl groups, cyclohexyl groups, and the like. Alkyl groups are saturated groups, unless it is a cyclic group. For example, an alkyl group is a Ci to C30 alkyl group, including all integer numbers of carbons and ranges of numbers of carbons therebetween (e.g., Ci, C2, C3, C4, C5, C6, C7, C8, C9, C10, Cll, C12, C13, C14, C15, C16, C17, C18, C19, C20, C21, C22, C23, C24, C25, C26, C27, C28, C29, and C30). The alkyl group may be unsubstituted or substituted with one or more substituents. Examples of substituents include, but are not limited to, halogens (-F, - Cl, -Br, and -I), aliphatic groups (e.g., alkyl groups, alkenyl groups, alkynyl groups, and the like), halogenated aliphatic groups (e.g., trifluoromethyl group), aryl groups, halogenated aryl groups, alkoxide groups, amine groups, nitro groups, carboxylate groups, carboxylic acids, ether groups, alcohol groups, alkyne groups (e.g., acetylenyl groups and the like), and the like, and combinations thereof.
[0029] The term “treatment” as used herein refers to reduction or delay in one or more symptoms or features associated with the presence of the particular condition being treated. Treatment does not necessarily mean complete cure and does not preclude relapse. Treatment may be carried out over a short period of time (days, weeks), or over a long period of time (months) or may be on a continuous basis (e.g., in the form of a maintenance therapy). Treatment may be continual or intermittent.
[0030] The term “therapeutically effective” dose or amount as used herein is the amount sufficient to achieve, in a single or multiple doses, the intended purpose of treatment. For example, an effective amount for effect wound healing is the amount sufficient to achieve one or more indicators of wound healing. The exact amount desired or required will vary depending on the mode of administration, patient specifics and the like. Appropriate effective amounts or the length of treatment can be determined by one of ordinary skill in the art (such as a clinician) with the benefit of the present disclosure.
[0031] The terms “anionic groups” and “anionically-modified corn starch particles” as used herein refers to groups that are either negatively charged or have the ability to be ionized such that the group has a negative charge. Examples of anionic groups or groups that would render a particle anionically modified include, but are not limited to, carboxylic acid groups or carboxylate groups, sulfonic groups, phosphate groups, or partially deprotonated/protonated species thereof.
[0032] The terms “cationic groups” and “cationically-modified corn starch particles” as used herein refers to groups that are either positively charged or have the ability to be ionized such that the group has a positively charge. Examples of cationic groups or groups that would render a particle cationically modified include, but are not limited to, alkylated ammonium groups or amine groups. Various examples of alkylated ammonium groups include, but are not limited to, trimethylammonium groups or dimethylammonium groups. [0033] The present disclosure provides starch-based particles. Also provided are compositions comprising the starch-based particles, food products comprising the starch- based particles, and methods of making the starch-based particles.
[0034] In an aspect, the present disclosure provides starch-based particles. The starch- based particle may have a longest linear dimension (e.g., diameter) is 10-25 pm, including all 0.1 pm values and ranges therebetween.
[0035] In an embodiment, the starch-based particles have a core and a plurality of domains, wherein the plurality of domains are on an exterior surface of the starch-based particle, wherein the plurality of domains are a positively charged starch and the core is negatively charged or capable of being ionized to a negative charge.
[0036] The core may be negatively charged or capable of having a negative charge. For example, the core may be functionalized with one or more carboxylic acid groups or carboxylate groups, sulfonic groups, phosphate groups, partially deprotonated/protonated species thereof, or similar group. In various embodiments, the core has one or more carboxylic acid groups or carboxylate groups.
[0037] The cores may comprise various starches. For example, the starch may be a starch with a granular size of greater than or equal to 10 pm. Examples of such starches include, but are not limited to, potato starch, wheat starch, corn starch, barley starch, pea starch, tapioca starch, and the like, and various combinations thereof. In various embodiments, the comprises corn starch. In various examples, when the starch is corn starch, the corn starch may have an amylose content of 0-75%, including all 0.1 values and ranges therebetween (e.g., 0%, 25%, 55%, or 70% (e.g., 55%)).
[0038] The domains are positively charged or capable of having a positive charge. For example, the domains may comprise one or more alkylated ammonium groups (e.g., trimethylammonium groups or one or more dimethylammonium groups). In various embodiments, the domains comprise one or more trimethylammonium groups.
[0039] The domains may comprise various starches. For example, the starch has a granular size of less than 10 pm. Examples of such starches include, but are not limited to,
amaranth starch, riche starch, quinoa starch, taro starch, and the like, and various embodiments thereof. In various examples, the domains comprise amaranth starch. [0040] In various examples, when the core comprises corn starch and the domains comprise amaranth starch, the ratio of amaranth starch to com starch is 10:1 to 50: 1 and the ratio is a weight percent ratio, including all integer ratio values and ranges therebetween. [0041] The starch-based particles may comprise one or more cationically-modified starch particles (e.g., cationically-modified amaranth starch particles) fused to an anionically- modified starch particle (e.g., anionically-modified corn starch particle), wherein at least a portion of a surface of the one or more cationically-modified starch particles (e.g., cationically-modified amaranth starch particles) is displayed on an exterior surface of the anionically-modified starch particle (e.g., anionically-modified corn starch particle). The anionically-modified starch particle (e.g., anionically-modified corn starch particle) may have one or more carboxylic acid groups or carboxylate groups, sulfonic groups, phosphate groups, partially deprotonated/protonated species thereof, or similar group. In various embodiments, the anionic groups are carboxylic acid groups or carboxylate groups. The cationically-modified starch particles (e.g., cationically-modified amaranth starch particles) may have one or more alkylated ammonium groups (e.g., trimethylammonium groups or one or more dimethylammonium groups or one or more dimethylammonium groups). In various embodiments, the cationically-modified starch particles (e.g., cationically-modified amaranth starch particles) have one or more trimethylammonium groups.
[0042] The anionically-modified starch particle (e.g., anionically-modified com starch particle) may have an amylose content of 0-75%, including all 0.1 values and ranges therebetween (e.g., 0%, 25%, 55%, or 70% (e.g., 55%)) prior to fusion to the one or more cationically-modified starch particles (e.g., cationically-modified amaranth starch particles). The ratio of cationically-modified starch to anionically-modified starch (e.g., cationically- modified amaranth starch particles to anionically-modified corn starch particle) is 10: 1 to 50: 1 and the ratio is a weight percent ratio, including all integer ratio values and ranges therebetween.
[0043] In an aspect, the present disclosure provide compositions comprising one or more starch-based particles. The composition may be is a powder, tablet, paste, suspension, slurry, capsule, or gel. In various embodiments, the composition may be added to a medium to thicken or otherwise increase the viscosity of the medium.
[0044] Without intending to be bound by any particular theory, the starch-based particles trap water by self-association (e.g., aggregation) due to Coulombic interactions. A
composition may comprise 0.01-99% by weight of the starched-based particles, including all 0.01 values and ranges therebetween (e.g., 1-40% by weight). A composition comprising the starch-based particles of the present disclosure has a viscosity higher than that of a composition comprising the same amount of unmodified or commercial cornstarch. In various embodiments, the viscosity of the composition comprising the starch-based particles of the present disclosure at 10 s'1 shear rate is > 1000-fold higher than the viscosity of a composition comprising unmodified or commercial cornstarch at the same 25% by weight concentration.
[0045] In various embodiments, a composition comprises starch-based particles that increase the viscosity or thicken relative to the same composition in the absence of the starch- based particles. In other embodiments, the composition may be added to a medium for the purpose of increasing the viscosity or thicken and/or to texturize the medium.
[0046] In various embodiments, the starch-based particles may aggregate into clusters or aggregates comprising a plurality of starch-based particles. In various embodiments, the aggregates may comprise at least 20 starch-based particles. In various embodiments, at least 80% (e.g., at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, or at least 95%) of the starch-based particles have formed aggregates comprising at least 20 starch-based particles. In various examples, the aggregates may have an average size of 400 pm2 or larger (e.g., 437 pm2). Aggregation may be seen in compositions having a concentration of 2 weight percent starch-based particles.
[0047] The composition may have desirable rheological properties. For example, the composition comprising a plurality of the starch-based particles may have a storage modulus of >103 Pa at a frequency of 1 Hz at a concentration of 25% by weight the starch-based particles. The composition may be a slurry. In various other embodiments, the composition comprising a plurality of the starch-based particles may have a viscosity of > 10 Pa s at a shear rate of 0.1 s'1 at a concentration of 25% by weight of the starch-based particles.
[0048] In various embodiments, the composition is a food additive. The food additive may be a thicken or texturizer. For example, the composition (e.g., food additive) may be added to or mixed into a food product for ingestion to thicken, texturize, or increase the viscosity of the food product. For example, the amount of the composition added to the food product may be varied to adjust the desired viscosity of the food product. For example, the composition (e.g., food additive) may be a powder, tablet, paste, suspension, slurry, capsule, or gel prior to addition to the food. Following addition of the composition, the viscosity or the
texture of the food product is changed. For example, following addition of the composition, the viscosity of the food product is increased relative to its viscosity prior to the addition of the food additive.
[0049] In various other embodiments, the composition may be suitable for delivery or vehicle for an agent (e.g., a pharmaceutical agent). For example the agent may be one or more small molecules and/or one or more biologically active components.
[0050] Compositions of the disclosure can comprise more than one pharmaceutical agent. For example, a first composition comprising a compound of the disclosure and a first pharmaceutical agent can be separately prepared from a composition which comprises the same compound of the disclosure and a second pharmaceutical agent, and such preparations can be mixed to provide a two-pronged (or more) approach to achieving the desired prophylaxis or therapy in an individual. Further, compositions of the disclosure can be prepared using mixed preparations of any of the compounds disclosed herein.
[0051] The composition may comprise one or more small molecules. Examples of small molecules include, but are not limited to, antibiotics, antifungals, chemotherapy agents, antivirals, analgesics, anesthetics, antiparasitics, anti-septic agents, other wound healing agents, and the like, and combinations thereof.
[0052] The composition may comprise one or more biologically active components. In various examples, the biologically active component is a biologic. The biologically active component may be a protein, peptide, cDNA, siRNA, mRNA, monoclonal antibodies, or the like, or any combination thereof.
[0053] Examples of agents include, but are not limited to, anti-androgens (e.g., Casodex, Flutamide, MDV3100, or ARN-509, Enzaluatide, apalutamide, darolutamid and abiraterone), MEK (e.g. MEK1, MEK2, or MEK1 and MEK2) inhibitors (e.g. XL518, CI- 1040, PD035901, selumetinib/AZD6244, GSK1120212/trametinib, GDC-0973, ARRY-162, ARRY-300, AZD8330, PD0325901, U0126, PD98059, TAK-733, PD318088, AS703026, BAY 869766), BRAF inhibitor (e.g. Vemurafenib), CDK4/6 inhibitors, SHP1 inhibitors, SHP2 inhibitors (e.g. TNO155; RMC-4630), PTPN22 inhibitors, PTPN1 inhibitors, PTPN2 inhibitors, CCR2 inhibitors, CXCR2 inhibitors, TORC1/TORC 2 inhibitors, PI-3K-AKT inhibitors, PARP inhibitors (e.g. Olaparib, Niraparib, Rucaparib), CDK4/6 inhibitors, CDK2 inhibitors, CDK7 inhibitors, TEAD inhibitors, alkylating agents (e.g., cyclophosphamide, ifosfamide, chlorambucil, busulfan, melphalan, mechlorethamine, uramustine, thiotepa, nitrosoureas, nitrogen mustards (e.g., mechloroethamine, cyclophosphamide, chlorambucil, meiphalan), ethylenimine and methylmelamines (e.g., hexamethlymelamine, thiotepa), alkyl
sulfonates (e.g., busulfan), nitrosoureas (e.g., carmustine, lomusitne, semustine, streptozocin), triazenes (decarbazine)), anti-metabolites (e.g., 5 -azathioprine, leucovorin, capecitabine, fludarabine, gemcitabine, pemetrexed, raltitrexed, folic acid analog (e.g., methotrexate), pyrimidine analogs (e.g., fluorouracil, fl oxouridine, Cytarabine), purine analogs (e.g., mercaptopurine, thioguanine, pentostatin), etc.), plant alkaloids (e.g., vincristine, vinblastine, vinorelbine, vindesine, podophyllotoxin, paclitaxel, docetaxel, etc.), topoisomerase inhibitors (e.g., irinotecan, topotecan, amsacrine, etoposide (VP 16), etoposide phosphate, teniposide, etc.), antitumor antibiotics (e.g., doxorubicin, adriamycin, daunorubicin, epirubicin, actinomycin, bleomycin, mitomycin, mitoxantrone, plicamycin, etc.), platinum-based compounds (e.g. cisplatin, oxaloplatin, carboplatin), anthracenedione (e.g., mitoxantrone), substituted urea (e.g., hydroxyurea), methyl hydrazine derivative (e.g., procarbazine), adrenocortical suppressant (e.g., mitotane, aminoglutethimide), epipodophyllotoxins (e.g., etoposide), enzymes (e.g., L-asparaginase), inhibitors of mitogen-activated protein kinase signaling (e.g. U0126, PD98059, PD184352, PD0325901, ARRY-142886, SB239063, SP600125, or BAY 43-9006), inhibitors of phosphatidylinositol 3-kinase signaling (e.g. wortmannin or LY294002), mTOR inhibitors, antibodies (e.g., rituxan), MAP4K1 inhibitor (e.g ZYF0033), 5-aza-2'-deoxycytidine, doxorubicin, vincristine, etoposide, gemcitabine, imatinib (Gleevec®), geldanamycin, dasatinib, 17-N-Allylamino-17- Demethoxygeldanamycin (17-AAG), bortezomib, carfilzomide, trastuzumab, anastrozole; angiogenesis inhibitors; antiandrogen, antiestrogen; antisense oligonucleotides; apoptosis gene modulators; apoptosis regulators; arginine deaminase; BCR/ABL antagonists; beta lactam derivatives; bFGF inhibitor; bicalutamide; camptothecin derivatives; casein kinase inhibitors (e.g., ICOS, Silmitasertib); clomifene analogues; cytarabine dacliximab; dexamethasone; estrogen agonists; estrogen antagonists; etanidazole; etoposide phosphate; exemestane; fadrozole; finasteride; fludarabine; fluorodaunorunicin hydrochloride; gadolinium texaphyrin; gallium nitrate; gelatinase inhibitors; gemcitabine; glutathione inhibitors; hepsulfam; immunostimulant peptides; insulin-like growth factor- 1 receptor inhibitor; interferon agonists; interferons; interleukins; letrozole; leukemia inhibiting factor; leukocyte alpha interferon; leuprolide+estrogen+progesterone; leuprorelin; matrilysin inhibitors; matrix metalloproteinase inhibitors; MIF inhibitor; mifepristone; mismatched double stranded RNA; monoclonal antibody; mycobacterial cell wall extract; nitric oxide modulators; oxaliplatin; panomifene; pentrozole; phosphatase inhibitors; plasminogen activator inhibitor; platinum complex; platinum compounds; prednisone; proteasome inhibitors; protein A-based immune modulator; protein kinase C inhibitor; protein tyrosine
phosphatase inhibitors; purine nucleoside phosphorylase inhibitors; RAS famesyl protein transferase inhibitors; RAS inhibitors; RAS-GAP inhibitor; ribozymes; signal transduction inhibitors; signal transduction modulators; single chain antigen-binding protein; stem cell inhibitor; stem-cell division inhibitors; stromelysin inhibitors; synthetic glycosaminoglycans; tamoxifen methiodide; telomerase inhibitors; thyroid stimulating hormone; translation inhibitors; tyrosine kinase inhibitors; urokinase receptor antagonists; steroids (e.g., dexamethasone), finasteride, aromatase inhibitors, gonadotropin-releasing hormone agonists (GnRH) such as goserelin or leuprolide, adrenocorticosteroids (e.g., prednisone), progestins (e.g., hydroxyprogesterone caproate, megestrol acetate, medroxyprogesterone acetate), estrogens (e.g., diethlystilbestrol, ethinyl estradiol), antiestrogen (e.g., tamoxifen), androgens (e.g., testosterone propionate, fluoxymesterone), antiandrogen (e.g., flutamide), immunostimulants (e.g., Bacillus Calmette-Guerin (BCG), levamisole, interleukin-2, alphainterferon, etc.), monoclonal antibodies (e.g., anti-CD20, anti-CD22, anti CD25,anti-CD37, anti-CD38, anti-HER2, anti-CD52, anti-HLA-DR, anti Nectin-4, anti Trop2, anti-Mucl, anti- mesothelin, anti-alpha-folate, anti DLL3, anti-GPRNMB, anti-Glypican3, anti-VEGF, anti- EGFR monoclonal antibodies), immunotoxins (e.g., anti-CD33 monoclonal antibody- calicheamicin conjugate, anti-CD22 monoclonal antibody-pseudomonas exotoxin conjugate, anti-CD30 etc.), radioimmunotherapy (e.g., anti-CD20 monoclonal antibody conjugated to U lin, 90Y, or 1311, etc.), triptolide, homoharringtonine, dactinomycin, doxorubicin, epirubicin, topotecan, itraconazole, vindesine, cerivastatin, vincristine, deoxyadenosine, sertraline, pitavastatin, irinotecan, clofazimine, 5-nonyloxytryptamine, vemurafenib, dabrafenib, erlotinib, gefitinib, EGFR inhibitors, epidermal growth factor receptor (EGFR)- targeted therapy or therapeutic (e.g. gefitinib (Iressa™), erlotinib (Tarceva™), cetuximab (Erbitux™), lapatinib (Tykerb™), panitumumab (Vectibix™), vandetanib (Caprelsa™), afatinib/BIBW2992, CI-1033/canertinib, neratinib/HKI-272, CP-724714, TAK-285, AST- 1306, ARRY334543, ARRY-380, AG-1478, dacomitinib/PF299804, OSI-420/desmethyl erlotinib, AZD8931, AEE788, pelitinib/EKB-569, CUDC-101, WZ8040, WZ4002, WZ3146, AG-490, XL647, PD153035, BMS-599626), sorafenib, imatinib, sunitinib, dasatinib, pyrrolo benzodiazepines (e.g. tomaymycin), carboplatin, CC-1065 and CC-1065 analogs including amino-CBIs, nitrogen mustards (such as chlorambucil and melphalan), dolastatin and dolastatin analogs (including auristatins: e.g., monomethyl auristatin E), anthracycline antibiotics (such as doxorubicin, daunorubicin, etc.), duocarmycins and duocarmycin analogs, enediynes (such as neocarzinostatin and calicheamicins), leptomycin derivaties, maytansinoids and maytansinoid analogs (e.g. mertansine), methotrexate, mitomycin C,
taxoids, vinca alkaloids (such as vinblastine and vincristine), epothilones (e.g. epothilone B), camptothecin and its clinical analogs topotecan and irinotecan, or the like, vaccines (e.g., Bacillus Calmette-Guerin (BCG), CSF1R inhibitors (e.g., pexidartinib); class 3 receptor tyrosine kinases (RTKs), such as KIT, FLT3, and platelet-derived growth factor receptors PDGFRa and PDGFRp.
[0054] The compositions may be suitable for topical or transdermal application or oral administration. The compositions can be produced in any solid, liquid or semi-solid formulation, including creams, emulsions, anhydrous compositions, aqueous dispersions, oils, foams, lotions, gels, ointments, sprays or aerosols or any other form suitable via the skin or mucosal surface. The formulations can be incorporated into support materials that can be applied to a wound surface, such as, for example, bandages, gauzes, clothing, diapers, dressings, adhesive or non-adhesive patches, and the like. The formulations can also be incorporated into cosmetic materials, such as foundations, lipsticks, moisturizers, creams, masks, and the like.
[0055] The composition may comprise one or more cosmetic components. Examples of cosmetic components include, but are not limited to, scented ingredients (e.g., essential oils and the like), exfoliating agents (e.g., salicylic acid and the like), lubricants (e.g., hyaluronic acid and the like), anti-cellulite agents (e.g., caffeine and the like), and the like, and various combinations thereof. Other examples of any of the foregoing components are known in the art and may be suitable for use in the composition of the present disclosure. [0056] Addition ingredients may also optionally be included in the cosmetic compositions. Non-limiting examples include water, non-volatile fatty substances, inorganic pigments, soft focus particles/powders, fragrances, preservatives, coalescents, wetting agents, water-soluble solvents, emollients, suspending agents, surfactants, actives, and the like. One unique feature of the cosmetic compositions is that they may include water (aqueous compositions) or may be free of water (anhydrous compositions).
[0057] The compositions may include pharmaceutically or cosmetically acceptable excipients, such as, buffering agents, antioxidants, preservatives, colorants, carriers, diluents, adjuvants, salts, and the like. Suitable water soluble buffering agents include carbonates, phosphates, bicarbonates, citrates, borates, acetates, succinates and the like, such as sodium phosphate, citrate, borate, acetate, bicarbonate, carbonate and the like. These agents are advantageously present in amounts sufficient to maintain a pH of the system about 6, such as between about 7 to about 10 and more preferably about 7 to about 9. Suitable water soluble
preservatives include sodium bisulfite, sodium bisulfate, sodium thiosulfate, ascorbate, benzalkonium chloride, chlorobutanol, thimerosal, phenylmercuric acetate, phenylmercuric borate, phenylmercuric nitrate, parabens, methylparaben, polyvinyl alcohol, benzyl alcohol, phenylethanol and the like and mixtures thereof. The excipients may be present in amounts of from 0.001 to about 5% by weight, such as, for example, 0.01 to about 2% by weight. Pharmaceutical composition ingredients and preparation can be carried out by standard pharmaceutical formulation techniques such as those disclosed in Remington: The Science and Practice of Pharmacy (2012) 22nd Edition, Philadelphia, PA. Lippincott Williams & Wilkins.
[0058] In an aspect, the present disclosure provides food products. The food product may comprise the starch-based particles of the present disclosure or a composition comprising the starch-based particles of the present disclosures.
[0059] Various food products may comprise the starch-based particles of the present disclosure or a composition comprising the starch-based particles of the present disclosures. Non-limiting examples of food products include sauces, soups, fillings, custards, puddings, desserts, dressings, and the like. Other food products are known in the art and are within the scope of the present disclosure. The food products are suitable for ingestion may humans and/or animals.
[0060] In an aspect, the present disclosure provides methods of making the starch- based particles of the present disclosure.
[0061] In various embodiments, a method for making starch-based particles, comprises: hydrating partially gelatinized starch (e.g., com starch) and a different starch (e.g., amaranth starch) with water; combining the partially gelatinized starch (e.g., partially gelatinized corn starch) and the different starch (e.g., the amaranth starch) at a ratio of 10: 1 to 50: 1 by weight (partially gelatinized starch (e.g., partially gelatinized corn starch) to different starch (e.g., amaranth starch)) to form a mixture; incubating the mixture at a temperature in the range of 25-50 °C for 5 to 15 minutes; centrifuging the mixture at 8,000-15,000 g for 5- 15 minutes (min); and removing a supernatant from the mixture, where the starch-based particles remains. In various embodiments, the ratio of partially gelatinized starch and different starch (e.g., the partially gelatinized corn starch to amaranth starch) is 50: 1 by weight, including all ratio values and ranges therebetween.
[0062] In various embodiments, the partially gelatinized starch (e.g., the partially gelatinized corn starch) is modified such that it comprises one or more anionic groups (e.g., one or more carboxylic acid groups or carboxylate groups, sulfonic groups, phosphate
groups, or partially deprotonated/protonated species thereof). In various examples, the one or more anionic groups are carboxylate groups. The partially gelatinized starch may be com starch, potato starch, wheat starch, barley starch, pea starch, tapioca starch, or the like, or various combinations thereof. In various embodiments, the partially gelatinized starch is corn starch.
[0063] The different starch (e.g., starch other than com starch) (e.g., amaranth starch) may be modified such that is comprises one or more cationic groups (e.g., quaternary amines, such as, for example, alkylated amines). In various embodiments, one or more cationic groups are one or more trimethylammonium groups or one or more dimethylammonium groups. In various embodiments, the one or more cationic groups are one or more trimethylammonium groups. In various embodiments, the starch is amaranth starch, rice starch, quinoa starch, taro starch, or the like, or various combinations thereof. In various embodiments, the starch is amaranth starch.
[0064] In various embodiments, the partially gelatinized starch (e.g., partially gelatinized corn starch) and the different starch (e.g., amaranth starch) are hydrated with water at a ratio of 1 :5 (starch to water) by weight.
[0065] The steps of the method described in the various embodiments and examples disclosed herein are sufficient to carry out the methods of the present disclosure. Thus, in an embodiment, the method consists essentially of a combination of the steps of the methods disclosed herein. In another embodiment, the method consists of such steps.
[0066] The following Statements provide various embodiments of the present disclosure.
Statement 1. A starch-based particle having a core and a plurality of domains, wherein the plurality of domains are on an exterior surface of the starch-based particle, wherein the plurality of domains are a positively charged starch (e.g., a positively charged amaranth starch) and the core is negatively charged or capable of being ionized to a negative charge.
Statement 2. A starch-based particle according to Statement 1, wherein the core has one or more carboxylic acid groups or carboxylate groups, sulfonic groups, phosphate groups, or partially deprotonated/protonated species thereof.
Statement 3. A starch-based particle according to Statement 1 or Statement 2, wherein the core has one or more carboxylic acid groups or carboxylate groups.
Statement 4. A starch-based particle according to any one of the preceding Statements, wherein the domains have one or more trimethylammonium groups or one or more dimethylammonium groups.
Statement 5. A starch-based particle according to any one of the preceding Statements, wherein the domains have one or more trimethylammonium groups.
Statement 6. A starch-based particle according to any one of the preceding Statements, wherein at least one of the plurality of domains comprises amaranth starch, rice starch, quinoa starch, taro starch, or the like, or various combinations thereof.
Statement 7. A starch-based particle according to any one of the preceding Statements, wherein at least one of the plurality of domains comprises amaranth starch.
Statement 8. A starch-based particle according to any one of the preceding Statements, wherein the core comprises corn starch, potato starch, wheat starch, barley starch, pea starch, tapioca starch, or the like, or various combinations thereof.
Statement 9. A starch-based particle according to any one of the preceding Statements, wherein the core comprises corn starch.
Statement 10. A starch-based particle according to any one of the preceding Statements, wherein the core (e.g., corn starch) has an amylose content of 0-70%, including all 0.1% values and ranges therebetween.
Statement 11. A starch-based particle according to any one of the preceding Statements, wherein the core has an amylose content of 0%, 25%, 55%, or 70%.
Statement 12. A starch-based particle according to any one of Statements 9-11, wherein the corn starch has an amylose content of 55%.
Statement 13. A starch-based particle according to any one of Statements 7 or 9-12, wherein the ratio of amaranth starch to corn starch is 10: 1 to 50:1 and the ratio is a weight percent ratio.
Statement 14. A starch-based particle comprising one or more cationically-modified starch particles (e.g., cationically-modified amaranth starch particles) fused to an anionically- modified starch particle (e.g., anionically-modified corn starch particle), wherein at least a portion of a surface of the one or more cationically-modified starch particles (e.g., cationically-modified amaranth starch particles) is displayed on an exterior surface of the anionically-modified starch particle (e.g., anionically-modified corn starch particle).
Statement 15. A starch-based particle according to Statement 14, wherein at least a portion of the cationically-modified starch particles comprise amaranth starch, rice starch, quinoa starch, taro starch, or the like, or various combinations thereof.
Statement 16. A starch-based particle according to Statement 14 or Statement 15, wherein at least a portion of the cationically-modified starch particles comprise amaranth starch.
Statement 17. A starch-based particle according to any one of Statements 14-16, wherein the anionically-modified starch particle comprises corn starch, potato starch, wheat starch, barley starch, pea starch, tapioca starch, or the like, or various combinations thereof.
Statement 18. A starch-based particle according to any one of Statements 14-17, wherein the anionically-modified starch particle comprises com starch.
Statement 19. A starch-based particle according to Statement 18, wherein the anionically- modified starch particle (e.g., anionically-modified corn starch particle) has one or more carboxylic acid groups or carboxylate groups, sulfonic groups, phosphate groups, or partially deprotonated/protonated species thereof. In various embodiments, the anionically-modified starch particle (e.g., anionically-modified corn starch particle) has one or more carboxylic acid groups or carboxylate groups.
Statement 20. A starch-based particle according to any one of Statements 14-19, wherein the cationically-modified starch particles (e.g., cationically-modified amaranth starch particles) have one or more trimethylammonium groups or one or more dimethylammonium groups. In various embodiments, the cationically-modified starch particles (e.g., cationically-modified amaranth starch particles) have one or more trimethylammonium groups.
Statement 21. A starch-based particle according to any one of Statements 14-20, wherein the anionically-modified starch particle (e.g., anionically-modified corn starch particle) has an amylose content of 0-70% prior to fusion to the one or more cationically-modified starch particles (e.g., cationically-modified amaranth starch particles). In various embodiments, the corn starch has an amylose content of 0%, 25%, 55%, or 70% prior to fusion to the one or more cationically-modified starch particles (e.g., cationically-modified amaranth starch particles). In various embodiments, the anionically-modified starch particle (e.g., anionically- modified corn starch particle) has an amylose content of 55% prior to fusion to the one or more cationically-modified starch particles (e.g., cationically-modified amaranth starch particles).
Statement 22. A starch-based particle according to any one of Statements 14-21, wherein the ratio of cationically-modified starch to anionically-modified starch (e.g., cationically- modified amaranth starch to anionically-modified com starch) is 10: 1 to 50: 1 and the ratio is a weight percent ratio.
Statement 23. A starch-based particle according to any one of the preceding Statements, wherein the starch-based particle is 10-25 pm, including all 0.1 pm values and ranges therebetween.
Statement 24. A composition comprising one or more starch-based particles according to any one of the preceding Statements.
Statement 25. A composition according to Statement 24, wherein the composition is a powder, tablet, paste, suspension, slurry, capsule, or gel.
Statement 26. A composition according to Statement 24 or Statement 25, comprising one or more aggregates comprising the one or more starch-based particles according to any one of Statements 1-23.
Statement 27. A composition according to Statement 26, wherein a portion of the aggregates individually comprise at least 20 starch-based particles.
Statement 28. A composition according to Statement 26 or Statement 27, wherein at least 80% of the starch-based particles have formed aggregates comprising at least 20 starch-based particles.
Statement 29. A composition according to any one of Statements 24-28, wherein the aggregates have an average size of 400 pm2 or larger. This size is an area of aggregation from image processing during microscopy.
Statement 30. A composition according to any one of Statements 24-29, wherein the composition has a storage modulus of >103 Pa at a frequency of 1 Hz.
Statement 31. A composition according to any one of Statements 24-30, wherein the composition is 25% by weight the starch-based particles.
Statement 32. A composition according to any one of Statements 24-31, wherein the composition is a food additive.
Statement 33. A composition according to any one of Statements 24-32, wherein the composition is a thickener or a texturizer.
Statement 34. A composition according to any one of Statements 24-33, wherein the one or more starch-based particles are present at a concentration of 1-40% by weight.
Statement 35. A composition according to any one of Statements 24-31, 33, or 34, further comprising one or more small molecules and/or biologically active component.
Statement 36. A composition according to Statement 35, wherein the one or more small molecules are chosen from antibiotics, antifungals, chemotherapy agents, antivirals, analgesics, anesthetics, and the like, and combinations thereof.
Statement 37. A composition according to Statement 35, wherein the biologically active component is a biologic.
Statement 38. A composition according to Statement 35 or Statement 37, wherein the biologically active component is a protein, peptide, cDNA, siRNA, mRNA, monoclonal antibodies, or the like, or any combination thereof.
Statement 39. A composition according to any one of Statements 24-31 or 33-38, further comprises one or more cosmetic components.
Statement 40. A composition according to Statement 39, wherein the one or more cosmetic components are chosen from scented ingredients (e.g., essential oils and the like), exfoliating agents (e.g., salicylic acid and the like), lubricants (e.g., hyaluronic acid and the like), anticellulite agents (e.g., caffeine and the like), and the like, and various combinations thereof.
Statement 41. A food product comprising the one or more starch-based particles according to any one of Statements 1-23 or the composition according to any one of Statements 24-33.
Statement 42. A food product according to Statement 41, wherein the food product is a sauce, a soup, a filling, a custard, a pudding, a dessert, a dressing, or the like.
Statement 43. A method for making starch-based particles according to any one of Statements 1-23, comprising: hydrating partially gelatinized starch (e.g., partially gelatinized corn starch) and a different starch (e.g., amaranth starch) with water; combining the partially gelatinized corn starch and amaranth starch at a ratio of 10:1 to 50:1 by weight (partially gelatinized corn starch to amaranth starch) to form a mixture; incubating the mixture at a temperature in the range of 25-50 °C for 5 to 15 minutes; centrifuging the mixture at 8, GOO- 15, 000 g for 5 to 15 min; and removing a supernatant from the mixture, wherein the starch- based particles remains.
Statement 44. A method according to Statement 43, wherein at least a portion of the different starch comprises amaranth starch, rice starch, quinoa starch, taro starch, or the like, or various combinations thereof.
Statement 45. A method according to Statement 43 or Statement 44, wherein at least a portion of the cationically-modified starch particles comprise amaranth starch.
Statement 46. A method according to any one of Statements 43-45, wherein the partially gelatinized starch comprises corn starch, potato starch, wheat starch, barley starch, pea starch, tapioca starch, or the like, or various combinations thereof.
Statement 47. A method according to any one of Statements 43-46, wherein the partially gelatinized starch comprises corn starch.
Statement 48. A method according to any one of Statements 43-47, wherein the ratio of partially gelatinized starch (e.g., partially gelatinized corn starch) and different starch (e.g., amaranth starch) is 50: 1 by weight.
Statement 49. A method according to any one of Statements 43-48, wherein the partially gelatinized starch (e.g., partially gelatinized com starch) is modified such that it comprises one or more anionic groups.
Statement 50. A method according to Statement 49, wherein the one or more anionic groups are carboxylic acid groups or carboxylate groups, sulfonic groups, phosphate groups, or partially deprotonated/protonated species thereof.
Statement 51. A method according to Statement 49 or Statement 50, wherein the one or more anionic groups are carboxylate groups.
Statement 52. A method according to any one of Statements 43-51, wherein the different starch (e.g., amaranth starch) is modified such that is comprises one or more cationic groups.
Statement 53. A method according to Statement 52, wherein the one or more cationic groups are quaternary amines.
Statement 54. A method according to Statement 53, wherein the quaternary amines are alkylated ammonium groups.
Statement 55. A method according to Statement 54, wherein the alkylated ammonium groups are trimethylammonium groups or dimethylammonium groups.
Statement 56. A method according to any one of Statement 54 or Statement 55, wherein the alkylated ammonium group is a trimethylammonium group.
Statement 57. A method according to any one of Statements 43-56, wherein the partially gelatinized starch (e.g., partially gelatinized starch) and different starch (e.g., amaranth starch) are hydrated with water at a ratio of 1 :5 (starch to water) by weight.
[0067] The following example is presented to illustrate the present disclosure. It is not intended to be limiting in any matter.
EXAMPLE
[0068] This example provides a description of particles of the present disclosure.
[0069] The work presented here describes a new approach to develop a scalable modification method to yield a heterogeneous surface on com starch granules.
[0070] The granular size of starch depends on the botanical sources and can vary from 1 pm (amaranth starch) to over 50 pm (potato starch). A possible approach to prepare a fused starch particle is partial gelatinization. Alcohols precipitate starch from aqueous solutions and have been used to limit the degree of gelatinization. With the hydrothermal treatment in aqueous alcohols, the granules would still maintain the intact shape, even though the double helices of starch dissociate. Alcohols have also been shown to enter the single helix of amylose forming metastable inclusion complexes. When the partially gelatinized starch was redispersed in water, the granules swell, and exhibit lower particle stiffness and higher deformability due to the decreased crystallinity. It was hypothesized that the swollen starch would fuse particles together as the conformational entropy of the polymer chains increases with partial gelatinization, and the tangled chains would fuse after dehydration reforming crystallized particles. In addition to surface modifications, this project investigated methods for creating charged starches to fabricate starch-based patchy particles with a negatively charged core and positively charged patches. Our design aims to allow starch granules to interact and associate into superstructures that could be able to trap water and improve viscoelasticity. The starch with the enhanced rheological properties would act as stronger thickener and as such the food industry could use less starch to achieve the same textures, and consumers can reduce the calorie intake from the energy dense carbohydrates. [0071] Materials and methods.
[0072] Materials. Corn starch (Hylon V, amylose content = 55%) was purchased from Ingredion (IL, USA). Ethyl alcohol (> 99% purity) was purchased from bioPLUS (NY,
USA). Chloroacetic acid, sodium hydroxide, epoxy-propyltrimethylammonium chloride (ETMAC), sodium chloride, and calcium chloride were obtained from Sigma-Aldrich (MO, USA).
[0073] Extraction of amaranth starch. The amaranth starch was extracted from amaranth flour by a previously published method. Specifically, amaranth flour (100 g) was blended with 500 mL of a 0.15 % w/v NaOH solution at ambient temperature for 60 min. The mixture then was sieved (53 pm mesh opening, VWR, IL, USA) with a laboratory shaker (Derrick Mfg. Co., Buffalo, NY, USA). The fine starch granules dispersed in liquid passed through the sieve and the remaining solid was redispersed in fresh NaOH solution (100 mL) followed by another 10 min of mixing. The extract was filtered using the sieve with 53 pm mesh opening and combined with the first batch, which was then centrifuged at 3,000 g for 20 min. The supernatant was discarded, and the top brown protein layer was removed using spatula. The sediments were redispersed in deionized water with pH adjusted to 6.0 ± 0.1 using 1 M HC1. The yellow protein layer that formed after pH adjustment was removed again to purify the starch. The remaining lower white layer was freeze-dried and ground into powders. The isolated starch contained 2.4% protein and 2.2% fat.
[0074] Preparation of partially gelatinized starch. The starch was partially gelatinized by hydrothermal processing in alcohol as previously published. Specifically, 100 g of native starch was mixed with 500 mL of aqueous ethanol (50% v/v for amaranth starch and 30% v/v for corn starch). The starch-in-solvent suspensions were heated at 80 °C for 30 min. After thermal incubation, 100 mL ethanol was added to the slurry, and the starch was then filtered (Grade 1, Waterman). The filtered starch was washed three times with ethyl alcohol, and the solvent was removed in an oven at 80 °C for 8 h to remove residuals. The dry starch was ground with a homogenizer (Oster 2095357, FL, USA) for 2 min, and the powder was sieved (#50 mesh) then stored for future use.
[0075] Preparation of negatively charged corn starch. The corn starch was modified to carry a negative charge by the large based on the carboxylation by chloroacetic acid. Specifically, 50 g of NaOH was dissolved in 266 mL DI water, and 1,066 mL ethanol was added to the alkaline solution. Chloroacetic acid (81.3 g) was then added, and the mixture was stirred for 1 h, after which, 100 g of partially gelatinized com starch was mixed with the reaction solution. The mixture was stirred for 2 hours at room temperature, and the resulting slurry was filtered using a Whatman Grade 1 filter paper and the solid collected was washed with 80% ethanol. The washed starch was subsequently centrifuged at 3,000 g for 3 min and then washed with additional 80% ethanol and centrifuged twice more. The starch was then
dispersed in 200 mL DI water and 0.1 M HC1 was used to adjust the pH to 7 to neutralize residual NaOH. The neutralized starch was centrifuged (3000 g for 3 min) and washed twice to remove residual salts. The starch pellet was freeze-dried for further use.
[0076] Preparation of cationic amaranth starch. The amaranth starch was positively charged by a modification method previously established. Specifically, we dispersed 1 g amaranth starch in 2 mL of water containing 1.91 g of ETMAC. The pH of the slurry was adjusted to 10.5 using 0.1 M NaOH. The mixture was then stirred at room temperature for 24 hours after which, the slurry was centrifuged (5000 g for 3 min) and the sediment was further washed with DI water twice, and the collected starch was further washed using ethanol. The starch was dried in a ventilated oven at room temperature.
[0077] Preparation of patchy starch via particle fusion. Separately, partially gelatinized corn starch and amaranth starch were hydrated with excess water (starch:water ratio = 1 :5). Then these solutions were mixed (with amaranth-starch-to-com-starch ratio at 10: 1 or 50: 1), and incubated at different temperature (25, 40, or 50 °C) for 5 or 20 min. After incubation the solutions were centrifuged (8000 g, 12000 g, or 15000 g) for different durations (5 or 15 min). When the granules are swollen with water, the starch granules were less rigid, and the conformational freedom of polymer chains increases owing to less hydrogen bonding. Therefore, the swollen granules interpenetrated the other granules while being centrifuged, and the polymer chains tangled together. After centrifuging, the clear supernatant was decanted, and the starch was dried in a ventilated oven at room temperature for 96 h and then stored at 4 °C for further characterization.
[0078] Attenuated total reflectance-Fourier transform infrared spectroscopy (FTIR). The FTIR spectra of starches were measured with an ATR-FTIR (Affinity- IS, Shimadzu) to identify the chemical composition of the charge modification of starch. Samples were measured from 400 to 4000 cm'1 in transmittance mode with 2 cm'1 resolution and 128 scans. [0079] Zeta-potential. The zeta-potential of starches was measured with a NanoZS90 zeta-sizer (Malvern Instrument Ltd., UK) with a He/Ne laser (X = 633 nm) at 25 °C. Starch was homogenized in water (0.1%); the zeta-potential was calculated from electrophoretic mobility based on the Smouluchowski model and was reported as an average value from triplicates.
[0080] X-ray diffractometry (XRD). The XRD patterns of the starch samples were collected using a Bruker D8 Advance ECO powder diffractometer (MA, USA) operating at 40 kV and 25 mA with Cu Ka radiation. The samples were examined for the angles 29 between 5° and 40°.
[0081] Scanning electron microscopy (SEM). Samples were coated with Au-Pd using a sputter coater (Denton Desk V, NJ, USA). The coated samples were examined with an SEM (Zeiss Gemini 500, Jena, Germany). Objects were scanned with 1 keV and imaged by a high efficiency secondary electron detector with a 20.0 pm aperture.
[0082] Water-holding capacity. To study the water-holding capacity, 0.5 g dry starch was weighed in a 15 mL tube and 5 mL water was added. The slurry was mixed vigorously for 1 min. The self-assembly sedimentation occurred overnight, and the volume of the sediment was recorded. The water held in the slurry was calculated by deducting out supernatant volume. Experiments were carried out in triplicate.
[0083] Quantification of flocculation. To visualize the flocculation of the patchy particles, a diluted starch slurry (2%) was prepared. The slurry was vortexed and homogenized with a high-shear mixer at 5,000 rpm for 1 min, and 20 L of each sample was transferred to a glass slide and covered with slip. The suspension was examined by a Leica Model DMIL LED Inverted Phase Contrast Microscope (lOOx). For each sample, 10 images were taken which contained > 10,000 particles in total, and the particle size was quantified using ImageJ (vl.51, National Institute of Health, USA) with pixel calculation. The mean size (pm2) for each sample was recorded.
[0084] Rheological measurements. The dynamic oscillation study was conducted using a rheometer (Anton Paar MCR301, Graz, Austria) with a 25 mm parallel plate and the gap set at 0.5 mm. The slurry containing 25 wt% starch was prepared. The storage modulus (G’) and loss modulus (G”) were recorded using the amplitude sweep (1 Hz, 0.1-100% strain) to scan the linear region. The 0.3% strain was chosen, and the frequency sweep was conducted from 0.5-100 Hz. The rotational shear study was also carried out from 0.01-100 s'1 and viscosity was plotted against shear rate.
[0085] Statistical analysis. Analyses were carried out in triplicates and the results were presented as means ± standard deviations, which were tested by one-way analysis of variance (ANOVA) using JMP Pro (Version 14, SAS Institute, USA) to identify significant difference (p < 0.05).
[0086] Results and Discussion.
[0087] Fabrication of starch-based patchy particles.
[0088] The hydrogen bonding in starch can be disrupted by thermal processing at temperatures higher than its gelatinization temperature in aqueous alcohol. Ethanol as the precipitant of starch is able to inhibit amylose leaching and the original granular shape of the starch is maintained. This partial gelatinization allows the starch to absorb the water and the
swollen starch becomes softer, less crystalline. The XRD curves (Figure 1) indicate that native starch exhibits typical B-type crystals with peaks at 5.5°, 15°, 17°, 20°, and 22.5°, which were in agreement with the data reported previously. After partially gelatinized starch were produced by hydrothermal processing in aqueous alcohol, however, those peaks diminished suggesting the dissociation of the hydrogen bonding between polymer chains and thus lower crystallinity.
[0089] The partially gelatinized starch undergoes retrogradation, which refers to the spontaneous process by which disordered polymer chains recrystallize. The patchy starch after dehydration showed recovered crystallization compared with the partially gelatinized starch (Figure 1). During storage, water evaporates allowing the hydroxyl groups on the polymer chains to get close enough to reform the hydrogen bonds. Although retrogradation is usually considered an undesirable process for food products causing bread staling, it can also be utilized as an approach to construct patchy particles.
[0090] Patchy starch formed after centrifuging the partially gelatinized starch under the mild processing conditions of incubation at room temperature, followed by centrifugation at 8,000 g for 5 min (Figures 2a and 2b). The starch granules interpenetrated each other as the partially gelatinized swollen starch turned less rigid, then, after centrifugation and dehydration, the starch particles were fused together, though the connection was only less than one quarter of amaranth starch granule (Figure 2b). When the patchy starch was redispersed in water (Figure 2c), a considerable amount of amaranth starch granules dethatched as free particles in water, and only a small number remained attached to the main com starch particles. The weak connection, less than 0.25 pm, could be the reason for the free particles observed (Figure 2c).
[0091] When starch was incubated at 50 °C for 20 min followed by high-speed centrifugation (15,000 g)for 20 min, the morphology changed significantly, and there was almost no observable amaranth starch (Figure 2d) although the mixing ratios used were the same. The image captured at higher magnification (Figure 2e) shows the connection is much stronger such that almost the entire body of the small particle has been fused into the large particle suggesting that the higher incubation temperature and stronger centrifugation strengthened the connection. It would be reasonable to hypothesize that the amaranth particles could be completely engulfed as many of the small particles were missing (Figure 2d). When the patchy starch was re-dispersed in water (Figure 2f), only few free amaranth starch granules were observed. It should be noticed the starch presented in Figure 2 were all uncharged, suggesting that the majority of the small particles were physically grafted onto the
corn starch rather than attracted by the electrostatic interaction, which is also attributed to the stronger fusion of particles.
[0092] The principle behind fabricating starch-based patchy particles is attributed to the partially gelatinized and hydrated starch granules. The softening of the starch granule is an indication of the increased degree of freedom of polymer chains and then the strong centrifugation helps them penetrate into the other granules. The polymer chains tangle together, and during the processing of dehydration and refrigeration, can recrystallize through hydrogen bonding. This retrogradation allows multiple particles to fuse as a single particle. [0093] Although the intense treatment enhanced the connection between the patches and the primary granule, it was found that after treatment there was a small amount of amaranth starch granules extremely gelatinized, which was not entirely unexpected due to the elevated incubation temperature. During centrifugation these extremely swollen granules rise to the top of starch sediments due to their lighter density. This thin layer of gelatinized starch on the top retained moisture well and slowed down recrystallization. Therefore, an intermediate processing condition was used: incubation at 40 °C for 15 min followed by centrifugation at 12,000 g for 15 min. The patchy starch prepared under these conditions showed that about half of the particle body of the amaranth starch had fused (Figure 8a). A patch where a small particle had indicated that two particles were physically stitched together via molecular entanglement (Figure 8b). Because the intermediated conditions (incubation at 40 °C for 15 min, centrifugation at 12,000 g for 15 min) was able to produce fused particles with a shorter dehydration process, these samples were the focus of the studies herein.
[0094] Effect of charge and patchy modification on starch functionality
[0095] The infrared (FTIR) spectra of native corn starch and carboxylated corn starch has a band at 1750 cm'1 which is attributed to the C=O stretching from carboxyl groups (Figure 3a). The carboxyl modification gives the starch a negative charge which we observe at -19.1 mV at neutral pH (Figure 3c). The FTIR spectra shows that the native amaranth starch exhibits a band at 1750 cm'1 (Figure 3b) suggesting the presence of carbonyl groups, which can be attributed to the minor protein content (-2.5%) after extraction from flour. The negative zeta-potential (-19.4 mV) of the native amaranth starch was also rendered by the minor protein content (Figure 3d). After cationic modification using ETMAC, the amaranth starch had a zeta-potential of +19.6 mV (Figure 3d) and the carbonyl band on FTIR spectra was diminished, confirming that the ETMAC reacted with the carboxyl group of the proteins. Additionally, the new band at 1300 cm'1 can be attributed to the C-N stretch indicating the presence of the trimethyl ammonium group.
[0096] The charged starches were physically fused together and exhibited a negatively charged core and positively charged patches on the surface. When the charged patchy starch was re-dispersed in water, the particles were able to assemble via electrostatic interactions (Figure 4a) resulting a heterogeneous opacity, and the flocculated starch sedimented to the bottom after 10-min settling. The amount of water held in the sediments was quantified. The rheological moduli, and viscosity of uncharged, mixed charged, and patchy charged starches were also examined (Figure 4). The control group of uncharged starch held 2.1 g water per unit of starch in the slurry sediment, but when starch particles are oppositely charged (com starch negatively charged and amaranth positively charged) the mixture was able to hold 3.3 g water per unit of starch (Figure 4b). When the charged particles are physically fused into patchy starch, the water-holding capacity increased further to 5.7 g per unit starch. The rheological study shows that the slurry of uncharged mixed starch exhibits a weak storage modulus which was below detection limits when the angular frequency was higher than 10 s'1, suggesting that the control group behaves fluid-like (Figure 4c). However, the charged groups showed an increase in rheological moduli, and the G’ was higher than G” indicating that the behavior was dominated by storage modulus and the slurries showed gel-like behavior (Figure 4c). Improvement was also observed on the viscosity of the physically fused patchy starch with heterogeneously charged surface which was two-orders of magnitude higher compared with the uncharged starch (Figure 4d). The viscosity-enhancing effect was more pronounced when particles were physically stitched together when compared with the mixed charge particles. The higher flexibility of mixed particles is most likely why they were not as effective at trapping water. The slurry of native starch was a Newtonian fluid with a constant viscosity under shear, but the charged groups exhibited shear-thinning with low viscosity at higher shear rates, which can be attributed to the dissociation of short-distance electrostatic interactions when shear rate increased.
[0097] The charge-induced flocculation formed pockets which trapped water molecules and inhibited the movement of liquid which led to enhanced functionalities. Starch granules were dispersed individually in the slurry of native corn starch (Figure 9a), while the charged patchy starch in water showed significant flocculation (Figure 9b). The images examined by microscope were processed to quantitatively characterize the interaction between particles. The suspension of native com starch in water showed particle sizes calculated by pixels was 127.9 pm2 based on image processing of over 10,000 particles (Figure 5a). The particle distribution indicated that 51.4% of starch in native com starch samples are present as individual particles (Figure 5b). However, when starch was charged
and physically fused (Figure 3c), particles flocculated to a large extent, 86.2% of starch particles formed the large clumps (> 20 particles) and only 1.3% particles were in the individual state, with the average size of all particles in the sample as high as 437.3 pm2 (Figure 5d).
[0098] Effect of charge and patchy modification after gelatinization and mechanical processing on starch functionality
[0099] Starch present in foods is usually gelatinized. The viscoelasticity of a starch slurry after gelatinization at 90 °C for 10 min, showed that the charge modification and patchy fusion enhanced both storage and loss modulus, which is similar to the observation of the non-gelatinized starch (Figures 6a and 6b). This means that the heating process did not impair the charged-induced interaction. As mechanical stress is usually involved in food processing, the viscosity of gelatinized starch was tested after blending with a homogenizer for 5,000 rpm for 1 min. The shearing process after gelatinization was found to not be an issue for the charged-induced interaction meaning that this platform could be used as a shear- reversible thickener in the food industry. The difference between a mixed group and fused group was less obvious after homogenization (Figure 6c), which is likely due to the dissociation of the patchy construction at high shear.
[0100] Conclusions
[0101] The present disclosure provides a facile method for preparing patchy particles using two different sized starches as food-grade ingredients, and it is the first time a study of heterogeneous surface model has been extended to biodegradable natural materials. After partial gelatinization, the swollen starch granules were centrifuged and dehydrated, which yielded a corona-shaped patchy structure where the smaller amaranth starch grafted onto the larger corn starch particles. Further the patchy starch exhibited an anionic core and cationic patches after charge modification. The patchy particles also showed higher water-holding capacity as the interparticle interactions allowed water to be trapped in pockets of the superstructure formed by granules. This impacted the rheological properties with the enhanced storage modulus, loss modulus, and viscosity as compared to the native starch and the mixed charged starch with the same blending ratio between amaranth and com starch. The enhanced functionality of the patchy starch particles was stable to cooking and mechanical stress as the enhanced viscoelasticity was not impaired by the processing, showing potential as a shear-reversible texturizer in food products. It could be used to reduce the amount of calorie-dense starch from diets. Future work is needed to investigate the impact of fabrications, including patchiness and charge density, on the self-assembly properties, and
overall functionality. The effects of different environmental factors such as pH and ionic strength also need to be evaluated in order to incorporate the charged patchy particles into the complicated food matrix.
[0102] Although the present disclosure has been described with respect to one or more particular embodiments and/or examples, it will be understood that other embodiments and/or examples of the present disclosure may be made without departing from the scope of the present disclosure.
Claims
1. A starch-based particle having a core and a plurality of domains, wherein the plurality of domains are on an exterior surface of the starch-based particle, wherein the plurality of domains are a positively charged starch and the core is negatively charged or capable of being ionized to a negative charge.
2. The starch-based particle according to claim 1, wherein the core has one or more carboxylic acid groups or carboxylate groups, sulfonic groups, phosphate groups, or partially deprotonated/protonated species thereof.
3. The starch-based particle according to claim 2, wherein the core has one or more carboxylic acid groups or carboxylate groups.
4. The starch-based particle according to claim 1, wherein the domains have one or more trimethylammonium groups or one or more dimethylammonium groups.
5. The starch-based particle according to claim 4, wherein the domains have one or more trimethylammonium groups.
6. The starch-based particle according to claim 1, wherein at least one of the plurality of domains comprises amaranth starch, rice starch, quinoa starch, taro starch, or combinations thereof.
7. The starch-based particle according to claim 6, wherein at least one of the plurality of domains comprises amaranth starch.
8. The starch-based particle according to claim 1, wherein the core comprises corn starch, potato starch, wheat starch, barley starch, pea starch, tapioca starch, or combinations thereof.
9. The starch-based particle according to claim 8, wherein the core comprises corn starch.
10. The starch-based particle according to claim 1, wherein the core has an amylose content of 0-70%.
11. The starch-based particle according to claim 10, wherein the core has an amylose content of 0%, 25%, 55%, or 70%.
12. The starch-based particle according to claim 11, wherein the core has an amylose content of or about 55%.
13. The starch-based particle according to claim 1, wherein the core comprises corn starch and the plurality of domains comprise amaranth and the ratio of amaranth starch to corn starch is 10: 1 to 50:1 and the ratio is a weight percent ratio.
14. A starch-based particle comprising one or more cationically-modified starch particles fused to an anionically-modified starch particle, wherein at least a portion of a surface of the one or more cationically-modified starch particles is displayed on an exterior surface of the anionically-modified starch particle.
15. The starch-based particle according to claim 14, wherein at least a portion of the cationically-modified starch particles comprise amaranth starch, rice starch, quinoa starch, taro starch, or combinations thereof.
16. The starch-based particle according to claim 15, wherein at least a portion of the cationically-modified starch particles comprise amaranth starch.
17. The starch-based particle according to claim 14, wherein the anionically-modified starch particle comprises corn starch, potato starch, wheat starch, barley starch, pea starch, tapioca starch, or combinations thereof.
18. The starch-based particle according to claim 17, wherein the anionically-modified starch particle comprises corn starch.
19. The starch-based particle according to claim 17, wherein the anionically-modified com starch particle has one or more carboxylic acid groups or carboxylate groups, sulfonic groups, phosphate groups, or partially deprotonated/protonated species thereof.
20. The starch-based particle according to claim 17, wherein the anionically-modified com starch particle has one or more carboxylic acid groups or carboxylate groups.
21. The starch-based particle according to claim 15, wherein the cationically-modified amaranth starch particles have one or more trimethylammonium groups or one or more dimethylammonium groups.
22. The starch-based particle according to claim 21, wherein the cationically-modified amaranth starch particles have one or more trimethylammonium groups.
23. The starch-based particle according to claim 14, wherein the anionically-modified starch particle has an amylose content of 0-70% prior to fusion to the one or more cationically- modified starch particles.
24. The starch-based particle according to claim 16, wherein the ratio of cationically- modified starch to anionically-modified starch is 10: 1 to 50: 1 and the ratio is a weight percent ratio.
25. The starch-based particle according to claim 14, wherein the starch-based particle is 10- 25 pm.
26. A composition comprising one or more starch-based particles according to claim 1 or claim 14.
27. The composition according to claim 26, wherein the composition is a powder, tablet, paste, suspension, slurry, capsule, or gel.
28. The composition according to claim 26, comprising one or more aggregates comprising the one or more starch-based particles.
29. The composition according to claim 28, wherein a portion of the aggregates individually comprise at least 20 starch-based particles.
30. The composition according to claim 28, wherein at least 80% of the starch-based particles have formed aggregates comprising at least 20 starch-based particles.
31. The composition according to claim 21, wherein a portion of the individual aggregates have an average size of 400 pm2 or larger.
32. The composition according to claim 26, wherein the composition has a storage modulus of >103 Pa at a frequency of 1 Hz.
33. The composition according to claim 26, wherein the one or more starch-based particles are present at a concentration of 1-40% by weight relative to the total weight of the composition.
34. The composition according to claim 26, wherein the composition is 25% by weight the starch-based particles.
35. The composition according to claim 26, wherein the composition is a thickener or a texturizer.
36. The composition according to claim 26, wherein the composition is a food additive.
37. The composition according to claim 26, further comprising one or more small molecules and/or one or more biologically active components.
38. The composition according to claim 37, wherein the one or more small molecules are chosen from antibiotics, antifungals, chemotherapy agents, antivirals, analgesics, anesthetics, antiparasitics, and combinations thereof.
39. The composition according to claim 37, wherein the biologically active component is a biologic.
40. The composition according to claim 37, wherein the biologically active component is a protein, peptide, cDNA, siRNA, mRNA, monoclonal antibodies, or any combination thereof.
41. The composition according to claim 26, further comprises one or more cosmetic components.
42. The composition according to claim 41, wherein the one or more cosmetic components are chosen from scented ingredients, exfoliating agents, lubricants, anti-cellulite agents, and combinations thereof
43. A food product comprising the one or more starch-based particles according to claim 1 or claim 14.
44. The food product according to claim 43, wherein the food product is a sauce, a soup, a filling, a custard, a pudding, a dessert, or a dressing.
45. A method for making starch-based particles according to claim 1 or claim 14, comprising: hydrating partially gelatinized starch and a different starch with water; combining the partially gelatinized starch and the different starch at a ratio of 10: 1 to 50: 1 by weight (partially gelatinized corn starch to amaranth starch) to form a mixture; incubating the mixture at a temperature in the range of 25-50 °C for 5 to 15 minutes; centrifuging the mixture at 8,000-15,000 g for 5-15 min; and removing a supernatant from the mixture, wherein the starch-based particles remains.
46. The method according to claim 45, wherein at least a portion of the different starch comprises amaranth starch, rice starch, quinoa starch, taro starch, or combinations thereof.
47. The method according to claim 46, wherein at least a portion of the cationically-modified starch particles comprise amaranth starch.
48. The method according to claim 45, wherein the partially gelatinized starch comprises corn starch, potato starch, wheat starch, barley starch, pea starch, tapioca starch, or combinations thereof.
49. The method according to claim 48, wherein the partially gelatinized starch comprises corn starch.
50. The method according claim 45, wherein the ratio of partially gelatinized starch and different starch is 50: 1 by weight.
51. The method according to claim 45, wherein the partially gelatinized starch is modified such that it comprises one or more anionic groups.
52. The method according to claim 51, wherein the one or more anionic groups are carboxylic acid groups or carboxylate groups, sulfonic groups, phosphate groups, or partially deprotonated/protonated species thereof
53. The method according to claim 51, wherein the one or more anionic groups are carboxylate groups.
54. The method according to claim 45, wherein the different starch is modified such that is comprises one or more cationic groups.
55. The method according to claim 54, wherein the one or more cationic groups are quaternary amines.
56. The method according to claim 55, wherein the quaternary amines are alkylated ammonium groups.
57. The method according to claim 56, wherein the alkylated ammonium groups are trimethylammonium groups or dimethylammonium groups.
58. The method according to claim 56, wherein the alkylated ammonium group is a trimethylammonium group.
59. The method according to claim 56, wherein the partially gelatinized starch and different starch are hydrated with water at a ratio of 1 :5 (starch to water) by weight.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202263330470P | 2022-04-13 | 2022-04-13 | |
US63/330,470 | 2022-04-13 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2023201313A2 true WO2023201313A2 (en) | 2023-10-19 |
WO2023201313A3 WO2023201313A3 (en) | 2023-11-23 |
Family
ID=88330407
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2023/065747 WO2023201313A2 (en) | 2022-04-13 | 2023-04-13 | Charged starch-based particles |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2023201313A2 (en) |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3405731B2 (en) * | 1994-07-22 | 2003-05-12 | ソシエテ デ プロデュイ ネッスル ソシエテ アノニム | Food grade brand foodstuff containing high amylose starch particles and its preparation |
KR101179541B1 (en) * | 2003-04-25 | 2012-09-05 | 레킷트 벵키저 헬스케어(유케이)리미티드 | Thickenable compositions |
US8419976B2 (en) * | 2005-07-21 | 2013-04-16 | Basf Se | Polyelectrolyte complexes as thickeners for high ionic strength salt solutions |
US20110052660A1 (en) * | 2007-03-16 | 2011-03-03 | Board Of Regents Of The University Of Texas System | Ceramic scaffolds for bone repair |
US20090062233A1 (en) * | 2007-08-09 | 2009-03-05 | Xin Ji | Modified starch material of biocompatible hemostasis |
US9078818B1 (en) * | 2011-04-29 | 2015-07-14 | Michael Mark Anthony | Method of preparing a hair treatment formulation comprising nanoparticles in solution and method of hair treatment utilizing a treatment formulation comprising nanoparticles in solution |
-
2023
- 2023-04-13 WO PCT/US2023/065747 patent/WO2023201313A2/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2023201313A3 (en) | 2023-11-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6972255B2 (en) | Preparations, manufacturing methods and uses of hydrophobic therapeutic agents | |
Dhumal et al. | Ultrasound assisted engineering of lactose crystals | |
RU2413506C2 (en) | Particles for active ingredient delivery, method for making thereof and based compositions | |
CN101547903B (en) | 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl)]carbamoyl}amino)-3-fluorophenoxy]-n-methylpyridine-2-carboxamide monohydrate | |
JP2012511519A (en) | Controlled release composition | |
CN103781490A (en) | Cylodextrin complexation methods for formulating peptide proteasome inhibitors | |
TW200911762A (en) | Particulates of a CRTH2 antagonist | |
CN108367005A (en) | Include the dosage form composition of tyrosine protein kinase inhibitor | |
BG109539A (en) | Pellets contaiing venlafaxine hydrochloride | |
Ramachandran et al. | Development and in vitro evaluation of biodegradable chitosan microspheres loaded with ranitidine and cross linked with glutaraldehyde | |
CN103025318B (en) | Suspension containing (E)-3-(3-Acetyl-4-hydroxy-5-methoxy-phenyl)-N-(4-hydroxy-1-methyl-3-octyloxy-2-oxo-1,2-dihydro-quinolin-7-yl)-acrylamide and silicone oil and/or silicone oil derivative and bar composition | |
CN109071472A (en) | A kind of novel crystal forms and preparation method thereof of selectivity S1P1 receptor stimulating agent | |
CN107693772A (en) | For preparing the cyclodextrin method of peptide protease body inhibitor | |
EA032506B1 (en) | Improved forms of a pi3k delta selective inhibitor for use in pharmaceutical formulations | |
EP4181857A1 (en) | Preparations and compositions comprising polymer combination preparations | |
CN103965420B (en) | A kind of based on disulfide bond reduction response type degradable medicaments carrier and preparation and application | |
CN115279345A (en) | Amorphous solid dispersion of 8-chloro-N- (4- (trifluoromethoxy) phenyl) quinolin-2-amine | |
CN106176602B (en) | A kind of targeting is in the Docetaxel chitosan nano-micelle and preparation method and application of stomach organization | |
WO2023201313A2 (en) | Charged starch-based particles | |
CN107049988A (en) | Drug-carrying nanometer particle, hydrogel and its preparation method and application | |
CN105294715B (en) | The fumarate and its crystal formation of a kind of amino quinazoline derivative | |
EP2941437A1 (en) | Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof | |
CN105294718B (en) | The maleate and its crystal formation of a kind of amino quinazoline derivative | |
Sartori et al. | Efavirenz dissolution enhancement V-A combined top down/bottom up approach on nanocrystals formulation | |
CN105294716B (en) | Two salicylates and its crystal formation of a kind of amino quinazoline derivative |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23789160 Country of ref document: EP Kind code of ref document: A2 |